75 Daly JM, Newton JR, Mumford JA. Current perspectives on control of equine influenza. Vet Res. 2004;35:411.

76 Crouch CF, Daly J, Hannant D, et al. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an “American lineage” H3N8 virus. Vaccine. 2004;23:418.

77 Wood JM, Mumford J, Folkers C, et al. Studies with inactivated equine influenza vaccine. 1. Serological responses of ponies to graded doses of vaccine. J Hyg (Lond). 1983;90:371.

78 Townsend HGG, Morley PS, Newton JR, et al. Measuring serum antibody as a method of predicting infection and disease in horses during outbreaks of influenza. Wernery U, et al. Equine Infectious Diseases VIII: Proceedings of the Eighth International Conference. Newmarket, England: R & W Publications; 1999:33.

79 Mumford JA, Wood J. Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Stand. 1992;79:137.

80 Wood JM, Mumford JA, Dunleavy U, et al. Single radial immunodiffusion potency tests for inactivated equine influenza vaccines. Powell DG, . Equine Infectious Diseases V: Proceedings of the Fifth International Conference on Equine Infectious Diseases. Lexington, Ky: University Press of Kentucky; 1988:74.

81 Landolt GA, Townsend HG, Lunn DP. Equine influenza infection. In: Sellon DC, Long MT, editors. Equine infectious diseases. St Louis: Saunders; 2007:124.

82 Mumford J. Progress in the control of influenza. In: Plowright W, Rossdale PD, Wade JF, editors. Equine Infectious Diseases VI: Proceedings of the Sixth International Conference. Newmarket, England: R & W Publications; 1991:207.

83 Newton JR, Wood JL, Jessett D, et al. “Cross-protection” and “cross-reaction” with equine influenza vaccines. Vet Rec. 1999;145:647.

84 Newton JR, Townsend HG, Wood JL, et al. Immunity to equine influenza: relationship of vaccine-induced antibody in young thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet J. 2000;32:65.

85 Mumford J, Wood J. WHO/OIE meeting: consultation on newly emerging strains of equine influenza, 18–19 May 1992, Animal Health Trust, Newmarket, Suffolk, UK. Vaccine. 1993;11:1172.

86 Mumford JA. The diagnosis and control of equine influenza. Proceedings of the 36th Annual Convention of the American Association of Equine Practitioners. 1990:377.

87 Mumford EL, Traub-Dargatz JL, Carman J, et al. Occurrence of infectious upper respiratory tract disease and response to vaccination in horses on six sentinel premises in northern Colorado. Equine Vet J. 2003;35:72.

88 Townsend HGG. Current and new technologies for vaccines and vaccination decisions. Proceedings of the 51st Annual Convention of the American Association of Equine Practitioners, Seattle. 2005:446.

89 Minke JM, Toulemonde CE, Dinic S, et al. Effective priming of foals born to immune dams against influenza by a canarypox-vectored recombinant influenza H3N8 vaccine. J Comp Pathol. 2007;137:S76.

90 Cullinane AA. Updating equine influenza strains in a combined equine influenza and herpesvirus vaccine. Vet J. 2004;167:118.

91 Newton JR, Lakhani KH, Wood JL, Baker DJ. Risk factors for equine influenza serum antibody titres in young thoroughbred racehorses given an inactivated vaccine. Prev Vet Med. 2000;46:129.

92 Newton JR, Verheyen K, Wood JL, et al. Equine influenza in the United Kingdom in 1998. Vet Rec. 1999;145:449.

93 Liu IK, Pascoe DR, Chang LW, Zee YC. Duration of maternally derived antibodies against equine influenza in newborn foals. Am J Vet Res. 1985;46:2078.

94 Smith BP. Influenza in foals. J Am Vet Med Assoc. 1979;174:289.

95 Wilson WD, Robinson D. Field safety of a modified-live, cold-adapted intranasal equine influenza vaccine (Heska Flu Avert IN vaccine) in horses. J Equine Vet Sci. 2000;20:8.

96 Wilson WD, Chambers TM, Holland RE, et al. Intranasal vaccine for equine influenza: roundtable discussion, part 3. Equine Pract. 2000;22:18.

97 Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol. 2004;98:127.

98 Breathnach CC, Clark HJ, Clark RC, et al. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine. 2006;24:1180.

99 Lunn DP, Soboll G, Schram BR, et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine. 1999;17:2245.

100 Slater J. Equine herpesviruses. In: Sellon DC, Long MT, editors. Equine infectious diseases. St Louis: Saunders; 2007:134.

101 Foote CE, Gilkerson JR, Whalley JM, Love DN. Seroprevalence of equine herpesvirus 1 in mares and foals on a large Hunter Valley stud farm in years pre- and postvaccination. Aust Vet J. 2003;81:283.

102 Foote CE, Love DN, Gilkerson JR, et al. EHV-1 and EHV-4 infection in vaccinated mares and their foals. Vet Immunol Immunopathol. 2006;111:41.

103 Foote CE, Love DN, Gilkerson JR, Whalley JM. Detection of EHV-1 and EHV-4 DNA in unweaned thoroughbred foals from vaccinated mares on a large stud farm. Equine Vet J. 2004;36:341.

104 Pusterla N, Leutenegger CM, Wilson WD, et al. Equine herpesvirus-4 kinetics in peripheral blood leukocytes and nasopharyngeal secretions in foals using quantitative real-time TaqMan PCR. J Vet Diagn Invest. 2005;17:578.

105 Wood JL, Newton JR, Chanter N, Mumford JA. Association between respiratory disease and bacterial and viral infections in British racehorses. J Clin Microbiol. 2005;43:120.

106 Burrell MH, Wood JL, Whitwell KE, et al. Respiratory disease in thoroughbred horses in training: the relationships between disease and viruses, bacteria and environment. Vet Rec. 1996;139:308.

107 Hannant D. Respiratory viral diseases of horses: overview. Proceedings of the World Equine Airway Symposium. Guelph, Ontario, Canada: Lifelearn; 1998.

108 Allen GP. Epidemic disease caused by equine herpesvirus-1: recommendations for prevention and control. Equine Vet Educ. 2002;14:136.

109 Ostlund EN. The equine herpesviruses. Vet Clin North Am Equine Pract. 1993;9:283.

110 Henninger RW, Reed SM, Saville WJ, et al. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J Vet Intern Med. 2007;21:157.

111 Goehring LS, van Winden SC, van Maanen C, et al. Equine herpesvirus type 1—associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999–2003). J Vet Intern Med. 2006;20:601.

112 Patel JR, Bateman H, Williams J, Didlick S. Derivation and characterisation of a live equid herpes virus-1 (EHV-1) vaccine to protect against abortion and respiratory disease due to EHV-1. Vet Microbiol. 2003;91:23.

113 Moore BO, Koonse HJ. Inactivated equine herpesvirus 1 vaccine—Pneumabort-K. Proceedings of the 24th Annual Convention of the American Association of Equine Practitioners, St Louis. 1978:75.

114 Heldens JG, Hannant D, Cullinane AA, et al. Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares. Vaccine. 2001;19:4307.

115 Burrows R, Goodridge D, Denyer MS. Trials of an inactivated equid herpesvirus 1 vaccine: challenge with a subtype 1 virus. Vet Rec. 1984;114:369.

116 Goodman LB, Wagner B, Flaminio MJ, et al. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine. 2006;24:3636.

117 Allen GP, Yeargan MR, Turtinen LW, Bryans JT. A new field strain of equine abortion virus (equine herpesvirus-1) among Kentucky horses. Am J Vet Res. 1985;46:138.

118 Bass EP. Immunization with a modified live virus equine rhinopneumonitis vaccine and an aluminum hydroxide adsorbed equine influenza vaccine. Proceedings of the Twenty-fourth Annual Convention of the American Association of Equine Practitioners, St Louis. 1978:65.

119 Smith PM, Kahan SM, Rorex CB, et al. Expression of the full-length form of gp2 of equine herpesvirus 1 (EHV-1) completely restores respiratory virulence to the attenuated EHV-1 strain KyA in CBA mice. J Virol. 2005;79:5105.

120 Kendrick JW, Stevenson W. Immunity to equine herpesvirus 1 infection in foals during the first year of life. J Reprod Fertil Suppl. 1979;27:615.

121 van Maanen C, Flore PH, Minke J, et al. Immune response of foals after vaccination against EHV-1/EHV-4 and persistence of maternal antibodies. Equine Infectious Diseases VII: Proceedings of the Seventh International Conference on Equine Infectious Diseases. Tokyo: R & W Publications (Newmarket); 1994:351.

122 Dutta SK, Shipley WD. Immunity and the level of neutralization antibodies in foals and mares vaccinated with a modified live-virus rhinopneumonitis vaccine. Am J Vet Res. 1975;36(4 Pt 1):445.

123 Neely DP, Hawkins DL. A two-year study of the clinical and serologic responses of horses to a modified live-virus equine rhinopneumonitis vaccine. J Equine Med Surg. 1978;2:532.

124 Ellis JA, Steeves E, Wright AK, et al. Cell-mediated cytolysis of equine herpesvirus-infected cells by leukocytes from young vaccinated horses. Vet Immunol Immunopathol. 1997;57:201.

125 Foote CE, Love DN, Gilkerson JR, Whalley JM. Serological responses of mares and weanlings following vaccination with an inactivated whole virus equine herpesvirus 1 and equine herpesvirus 4 vaccine. Vet Microbiol. 2002;88:13.

126 Gilkerson JR, Whalley JM, Drummer HE, et al. Epidemiology of EHV-1 and EHV-4 in the mare and foal populations on a Hunter Valley stud farm: are mares the source of EHV-1 for unweaned foals. Vet Microbiol. 1999;68:27.

127 Thomson GW, McCready R, Sanford E, Gagnon A. Case report: an outbreak of herpesvirus myeloencephalitis in vaccinated horses. Can Vet J. 1979;20:22.

128 Kohn CW, Fenner WR. Equine herpes myeloencephalopathy. Vet Clin North Am Equine Pract. 1987;3:405.

129 Wilson WD. Equine herpesvirus 1 myeloencephalopathy. Vet Clin North Am Equine Pract. 1997;13:53.

130 Nugent J, Birch-Machin I, Smith KC, et al. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J Virol. 2006;80:4047.

131 Patel JR, Didlick S, Bateman H. Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally derived antibody: protection against EHV-1 infection. Equine Vet J. 2004;36:447.

132 Patel JR, Földi J, Bateman H, et al. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges. Vet Microbiol. 2003;92:1.

133 Paillot R, Ellis SA, Daly JM, et al. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine. 2006;24:1490.

134 Soboll G, Hussey SB, Whalley JM, et al. Antibody and cellular immune responses following DNA vaccination and EHV-1 infection of ponies. Vet Immunol Immunopathol. 2006;111:81.

135 Weerasinghe CU, Learmonth GS, Gilkerson JR, et al. Equine herpesvirus 1 glycoprotein D expressed in E. coli provides partial protection against equine herpesvirus infection in mice and elicits virus-neutralizing antibodies in the horse. Vet Immunol Immunopathol. 2006;111:59.

136 Minke JM, Fischer L, Baudu P, et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol. 2006;111:47.

137 Hamlen HJ, Timoney JF, Bell RJ. Epidemiologic and immunologic characteristics of Streptococcus equi infection in foals. J Am Vet Med Assoc. 1994;204:768.

138 Sellon DC. Streptococcal infections. In: Sellon DC, Long MT, editors. Equine infectious diseases. St Louis: Saunders; 2007:244.

139 Timoney JF, Qin A, Muthupalani S, Artiushin S. Vaccine potential of novel surface exposed and secreted proteins of Streptococcus equi. Vaccine. 2007;25:5583.

140 Sheoran AS, Sponseller BT, Holmes MA, Timoney JF. Serum and mucosal antibody isotype responses to M-like protein (SeM) of Streptococcus equi in convalescent and vaccinated horses. Vet Immunol Immunopathol. 1997;59:239.

141 Flock M, Jacobsson K, Frykberg L, et al. Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses. Infect Immun. 2004;72:3228.

142 Timoney JF. Strangles. Res Vet Sci. 1993;54:256.

143 Sheoran AS, Timoney JF, Holmes MA, et al. Immunoglobulin isotypes in sera and nasal mucosal secretions and their neonatal transfer and distribution in horses. Am J Vet Res. 2000;61:1099.

144 Walker JA, Timoney JF. Construction of a stable non-mucoid deletion mutant of the Streptococcus equi Pinnacle vaccine strain. Vet Microbiol. 2002;89:311.

145 Sweeney CR, Timoney JF, Newton JR, Hines MT. Streptococcus equi infections in horses: guidelines for treatment, control, and prevention of strangles. J Vet Intern Med. 2005;19:123.

146 Hoffman AM, Staempfli HR, Prescott JF, Viel L. Field evaluation of a commercial M-protein vaccine against Streptococcus equi infection in foals. Am J Vet Res. 1991;52:589.

147 Staempfli HR, Hoffman AM, Prescott JF, Viel L. Clinical evaluation of a commercial M-protein vaccine in naturally infected foals. Proceedings of the 37th Annual convention of the American Association of Equine Practitioners. 1991:259.

148 Rief JS, George JL, Shideler RK. Recent developments in strangles research: observations on the carrier state and evaluation of a new vaccine. Proceedings of the 27th Annual convention of the American Association of Equine Practitioners. 1981:33.

149 Li W, Fiala S, Gigson N, et al. Efficacy of a modified live Streptococcus equi vaccine in an equine experimental model. Proceedings of the Eighth International Conference on Equine Infectious Diseases, Dubai. 1998:232.

150 Galan JE, Timoney JF, Lengemann FW. Passive transfer of mucosal antibody to Streptococcus equi in the foal. Infect Immun. 1986;54:202.

151 Waller AS, Jolley KA. Getting a grip on strangles: recent progress towards improved diagnostics and vaccines. Vet J. 2007;173:492.

152 Jacobs AA, Goovaerts D, Nuijten PJ, et al. Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi. Vet Rec. 2000;147:563.

153 Kelly C, Bugg M, Robinson C, et al. Sequence variation of the SeM gene of Streptococcus equi allows discrimination of the source of strangles outbreaks. J Clin Microbiol. 2006;44:480.

154 Waller A, Flock M, Smith K, et al. Vaccination of horses against strangles using recombinant antigens from Streptococcus equi. Vaccine. 2007;25:3629.

155 Madigan JE, Pusterla N. Ehrlichial diseases. Vet Clin North Am Equine Pract. 2000;16:487.

156 Palmer JE. Potomac horse fever. Vet Clin North Am Equine Pract. 1993;9:399.

157 Rikihisa Y. Protection against murine Potomac horse fever by an inactivated Ehrlichia risticii vaccine. Vet Microbiol. 1991;27:339.

158 Ristic M, Holland CJ, Goetz TE. Evaluation of a vaccine for equine monocytic ehrlichiosis (Potomac horse fever). Powell DG, . Equine Infectious Diseases V: Proceedings of the Fifth International Conference on Equine Infectious Diseases. Lexington, Ky: University Press of Kentucky; 1988:206.

159 Sessions J, Dawson JE. Maryland field evaluation of the Potomac horse fever vaccine. Equine Pract. 1988;10:7.

160 Atwill ER, Mohammed HO. Evaluation of vaccination of horses as a strategy to control equine monocytic ehrlichiosis. J Am Vet Med Assoc. 1996;208:1290.

161 Atwill ER, Mohammed HO. Benefit-cost analysis of vaccination of horses as a strategy to control equine monocytic ehrlichiosis. J Am Vet Med Assoc. 1996;208:1295.

162 Dutta SK, Vemulapalli R, Biswas B. Association of deficiency in antibody response to vaccine and heterogeneity of Ehrlichia risticii strains with Potomac horse fever vaccine failure in horses. J Clin Microbiol. 1998;36:506.

163 Wilkins PA. Botulism. In: Sellon DC, Long MT, editors. Equine infectious diseases. St Louis: Saunders; 2007:372.

164 Swerczek TW. Toxicoinfectious botulism in foals and adult horses. J Am Vet Med Assoc. 1980;176:217.

165 Whitlock RH, Buckley C. Botulism. Vet Clin North Am Equine Pract. 1997;13:107.

166 Wilkins PA, Palmer JE. Botulism in foals less than 6 months of age: 30 cases (1989–2002). J Vet Intern Med. 2003;17:702.

167 Thomas RJ, Rosenthal DV, Rogers RJ. A Clostridium botulinum type B vaccine for prevention of shaker foal syndrome. Aust Vet J. 1988;65:78.

168 Crane SA, Whitlock RH, Buckley C, et al. Clostridium botulinum type-B toxoid for vaccination of adult horses, pregnant mares, and foals: a study of vaccination protocols. Proceedings of the 37th Annual Convention of the American Association of Equine Practitioners, San Francisco. 1991:611.

169 McCue PM, Hietala SK, Spensley MS, et al. Prevalence of equine viral arteritis in California horses. Calif Vet. 1991;45:24.

170 Timoney PJ, McCollum WH, Murphy TW, et al. The carrier state in equine arteritis virus infection in the stallion with specific emphasis on the venereal mode of virus transmission. J Reprod Fertil Suppl. 1987;35:95.

171 McCollom WH. Development of a modified virus strain and vaccine for equine viral arteritis. J Am Vet Med Assoc. 1969;155:318.

172 Balasuriya UBR, MacLachlan NJ. Equine viral arteritis. In: Sellon DC, Long MT, editors. Equine infectious diseases. St Louis: Saunders; 2007:153.

173 McCollum WH. Pathologic features of horses given avirulent equine arteritis virus intramuscularly. Am J Vet Res. 1981;42:1218.

174 Harry TO, McCollum WH. Stability of viability and immunizing potency of lyophilized, modified equine arteritis live-virus vaccine. Am J Vet Res. 1981;42:1501.

175 McCollom WH, Timoney PJ, Roberts AW, et al. Response of vaccinated and non-vaccinated mares to artificial insemination with semen from stallions persistently infected equine arteritis virus. Powell DG, . Equine Infectious Diseases V: Proceedings of the Fifth International Conference on Equine Infectious Diseases. Lexington, Ky: University Press of Kentucky; 1988:13.

176 Moore BD, Balasuriya UB, Nurton JP, et al. Differentiation of strains of equine arteritis virus of differing virulence to horses by growth in equine endothelial cells. Am J Vet Res. 2003;64:779.

177 Hullinger PJ, Wilson WD, Rossitto PV, et al. Passive transfer, rate of decay, and protein specificity of antibodies against equine arteritis virus in horses from a standardbred herd with high seroprevalence. J Am Vet Med Assoc. 1998;213:839.

178 McCollum WH. Studies of passive immunity in foals to equine viral arteritis. Vet Microbiol. 1976;1:45.

179 Nugent J, Sinclair R, deVries AA, et al. Development and evaluation of ELISA procedures to detect antibodies against the major envelope protein (G[L]) of equine arteritis virus. J Virol Methods. 2000;90:167.

180 Castillo-Olivares J, Wieringa R, Bakonyi T, et al. Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain. J Virol. 2003;77:8470.

181 Giese M, Bahr U, Jakob NJ, et al. Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus. Virus Genes. 2002;25:159.

182 Tobiasch E, Kehm R, Bahr U, et al. Large envelope glycoprotein and nucleocapsid protein of equine arteritis virus (EAV) induce an immune response in Balb/c mice by DNA vaccination: strategy for developing a DNA-vaccine against EAV-infection. Virus Genes. 2001;22:187.

183 Balasuriya UB, Heidner HW, Davis NL, et al. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine. 2002;20:1609.

184 Balasuriya UB, Heidner HW, Hedges JF, et al. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J Virol. 2000;74:10623.

185 Browning GF, Chalmers RM, Snodgrass DR, et al. The prevalence of enteric pathogens in diarrhoeic thoroughbred foals in Britain and Ireland. Equine Vet J. 1991;23:405.

186 Browning GF, Sykes JE, Huntington PJ, et al. Rotavirus infections in Australian foals. Aust Equine Vet. 1992;10:123.

187 Dwyer RM. Rotaviral diarrhea. Vet Clin North Am Equine Pract. 1993;9:311.

188 Dwyer RM. Equine rotavirus. In: Sellon DC, Long MT, editors. Equine infectious diseases. St Louis: Saunders; 2007:181.

189 Imagawa H, Wada R, Sugita S, et al. Passive immunity in foals of mares immunised with inactivated equine rotavirus vaccine. Wernery U, et al. Equine Infectious Diseases VIII: Proceedings of the Eighth International Conference. Newmarket, England: R & W Publications; 1999:210.

190 Elschner M, Schrader C, Hotzel H, et al. Isolation and molecular characterisation of equine rotaviruses from Germany. Vet Microbiol. 2005;105:123.

191 Gulati BR, Deepa R, Singh BK, Rao CD. Diversity in Indian equine rotaviruses: identification of genotype G10,P6(1) and G1 strains and a new VP7 genotype (G16) strain in specimens from diarrheic foals in India. J Clin Microbiol. 2007;45:972.

192 Browning GF, Begg AP. Prevalence of G and P serotypes among equine rotaviruses in the faeces of diarrhoeic foals. Arch Virol. 1996;141:1077.

193 Powell DG, Dwyer RM, Traub-Dargatz JL, et al. Field study of the safety, immunogenicity, and efficacy of an inactivated equine rotavirus vaccine. J Am Vet Med Assoc. 1997;211:193.

194 Sheoran AS, Karzenski SS, Whalen JW, et al. Prepartum equine rotavirus vaccination inducing strong specific IgG in mammary secretions. Vet Rec. 2000;146:672.

195 Barrandeguy M, Parreño V, Lagos Mármol M, et al. Prevention of rotavirus diarrhoea in foals by parenteral vaccination of the mares: field trial. Dev Biol Stand. 1998;92:253.

196 Dubey JP, Lindsay DS, Saville WJA, et al. A review of Sarcocystis neurona and equine protozoal myeloencephalitis (EPM). Vet Parasitol. 2001;95:89.

197 Witonsky S, Morrow JK, Leger C, et al. Sarcocystis neurona—specific immunoglobulin G in the serum and cerebrospinal fluid of horses administered S. neurona vaccine. J Vet Intern Med. 2004;18:98.

198 Marsh AE, Lakritz J, Johnson PJ, et al. Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine. Vet Ther. 2004;5:34.

199 Kaufmann AF, Fox MD, Kolb RC. Anthrax in Louisiana, 1971: an evaluation of the Sterne strain anthrax vaccine. J Am Vet Med Assoc. 1973;163:442.

200 Hjerpe CA. Bovine vaccines and herd vaccination programs. In Smith BP, editor: Large animal internal medicine, ed 2, St Louis: Mosby, 1996.

201 Tizard I. General principles of vaccination and vaccines. Veterinary immunology, an introduction. ed 4. Philadelphia: Saunders; 1992.

202 Kaeberle M. The elements of immunity. Large Anim Vet. 1991. July/August

203 Abbas AK, Lichtman AH, Pober JS. Antigen presentation and T cell recognition and molecular basis of T cell antigen recognition and activation. In: Cellular and molecular immunology. Philadelphia: Saunders; 1991.

204 Cortese VS, West KH, Hassard LE, et al. Clinical and immunologic responses of vaccinated and unvaccinated calves to infection with a virulent type II isolate of bovine viral diarrhea virus. J Am Vet Med Assoc. 1998;213:1312.

205 Cravens RL, Bechtol D. Clinical responses of feeder calves under a direct IBR and BVD challenge: a comparison of two vaccines and a negative control. Bovine Pract. 1991;26:154.

206 Bolin CA, Thiermann AB, Handsaker AL, Foley JW. Effect of vaccination with a pentavalent leptospiral vaccine on Leptospira interrogans serovar Hardjo type hardjo-bovis infection of pregnant cattle. Am J Vet Res. 1989;50:161.

207 Hogan JS, Weiss WP, Todhunter DA, et al. Efficacy of an Escherichia coli J5 mastitis vaccine in an experimental challenge trial. J Dairy Sci. 1992;75:415.

208 Naggan L. Principles of epidemiology, Class notes, Johns Hopkins School of Public Health and Hygiene, Summer Graduate Program in Epidemiology. 1994.

209 Ribble C. Assessing vaccine efficacy. Can Vet J. 1990;31:679.

210 Meinert CL. Clinical trials: design, conduct and analysis. New York: Oxford University Press, 1986.

211 Duffus WPH. Immunoprophylaxis. In: Hallwell REW, Gorman NT, editors. Veterinary clinical immunology. Philadelphia: Saunders, 1989.

212 Hoffman M. Determining what immune cells see. Res News. 1992;255:531.

213 Von Boehmer H, Kisielow P. How the immune system learns about self. Sci Am. 1991;265:74.

214 Blecha F. New approaches to increasing immunity in food animals. Vet Med. 1990:1241. November

215 Godson DL, Campos M, Babiuk LA. The role of bovine intraepithelial leukocyte-mediated cytotoxicity in enteric antiviral defense. Viral Immunol. 1992;5:13.

216 Denis M, et al. Infectious bovine rhinotracheitis (bovine herpesvirus-1): helper T cells, cytotoxic T cells, and NK cells. In: Goddeeris BML, Morrison WI, editors. Cell-mediated immunity in ruminants. Boca Raton, Fla: CW Press, 1994.

217 Parker WL, et al. Effects of vaccination at branding on serum antibody titers to viral agents of bovine respiratory disease (BRD) in newly weaned New Mexico calves. Proc West Sect Am Soc Anim Sci. 1993;44:132.

218 Kimman TG, Westenbrink F, Straver PJ. Priming for local and systematic antibody memory responses to bovine respiratory syncytial virus: effect of amount of virus, viral replication, route of administration, and maternal antibodies. Vet Immunol Immunopathol. 1989;22:145.

219 Pitcher PM. Influence of passively transferred maternal antibody on response of pigs to pseudorabies vaccines. Proceedings of the American Association of Swine Practitioners Annual Meeting. 1996.

220 Ellis JA, Hassard LE, Cortese VS, Morley PS. Effects of perinatal vaccination on humoral and cellular immune responses in cows and young calves. J Am Vet Med Assoc. 1996;208:393.

221 Ridge JP, Fuchs EJ, Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science. 1996;271:1723.

222 Sarzotti M, Robbins DS, Hoffman FM. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science. 1996;271:1726.

223 Forsthuber T, Hualin CY, Lewhmann V. Induction of T_H1 and T_H2 immunity in neonatal mice. Science. 1996;271:1728.

224 Bryan LA, Fenton RA, Misra V, Haines DM. Fatal generalized bovine herpesvirus type 1 infection associated with a modified live infectious bovine rhinotracheitis/parainfluenza-3 vaccine administered to neonatal calves. Can Vet J. 1994;35:223.

225 Zavy MT, Juniewicz PE, Phillips WA, VonTungeln DL. Effect of initial restraint, weaning, and transport stress on baseline and ACTH-stimulated cortisol responses in beef calves on different genotypes. Am J Vet Res. 1992;53:551.

226 Sconberg S, Nockels CF, Bennett BW. Effects of shipping, handling, adrenocorticotropic hormone, and epinephrine on α-tocopherol content of bovine blood. Am J Vet Res. 1993;54:1287.

227 VonTungeln DL. The effects of stress on the immunology of the stocker calf. Bovine Pract. 1986;18:109.

228 Mueller D, Noxon J. Anaphylaxis: pathophysiology and treatment. Compend Cont Educ (Pract Vet). 1990;12:157. February

229 Rude TA. Postvaccination type I hypersensitivity in cattle. Agri-Practice. 1990;11:29.

230 Johansen KA, Wannameuhler M, Rosenbusch RF. Biological reactivity of Moraxella bovis lipopolysaccharide. Am J Vet Res. 1990;51:46.

231 Shuster DE, Harmon RJ, Jackson JA, Hemken RW. Reduced lactational performance following intravenous endotoxin administration to dairy cows. J Dairy Sci. 1991;74:3407.

232 Henderson B, Wilson M. Modulins: a new class of cytokine-inducing, proinflammatory bacterial virulence factor. Inflamm Res. 1995;44:187.

233 Rietschel ET, Brade H. Bacterial endotoxins. Sci Am. 1992;267:54.

234 Compendium of veterinary products. ed 8. Port Huron, Mich: North American Compendiums; 2005.

235 Endsley JJ, Quade MJ, Terharr B, Roth JA. BHV-1 specific CD4+, CD*+, and γδ T cells in calves vaccinated with one dose of a modified live BHV-1 vaccine. Viral Immunol. 2002;15:385.

236 Fulton RW, Briggs RE, Payton ME, et al. Maternally derived humoral immunity to bovine viral diarrhea virus (BVDV) 1a, BVDV1b, BVDV2, bovine herpesvirus-1, parainfluenza-3 virus, bovine respiratory syncytial virus, Mannheimia haemolytica and Pasteurella multocida in beef calves, antibody decline by half-life studies and response to vaccination. Vaccine. 2004;22:643.

237 Patel JR, Shilletto RW. Modification of active immunization with live bovine herpesvirus 1 vaccine by passive viral antibody. Vaccine. 2005;23:4023.

238 Kendrick JW, York CJ, McKercher DG. A controlled field trial of a vaccine for infectious bovine rhinotracheitis. Proc U S Livestock Sanit Assoc. 1956;60:155.

239 Bordt DE, Thomas PC, Marshall RF. Early protection against infectious bovine rhinotracheitis with intramuscularly administered vaccine. Proceedings of the 79th Annual Meeting of the U.S. Animal Health Association. 1975:50.

240 Sutton ML. Rapid onset of immunity in cattle after intramuscular injection of a modified live virus IBR vaccine. Vet Med Small Anim Clin. 1980;75:1447.

241 Fairbanks K, Campbell J, Chase CL. Rapid onset of protection against infectious bovine rhinotracheitis with a modified live virus multivalent vaccine. Vet Ther. 2004;5:17.

242 Ellis J, Waldner C, Rhodes C, Ricketts V. Longevity of protective immunity to experimental bovine herpesvirus-1 infection following inoculation with a combination modified-live virus vaccine in beef calves. J Am Vet Med Assoc. 2005;227:123.

243 Kennedy PC, Richards WPC. The pathology of abortion caused by the virus of infectious bovine rhinotracheitis. Pathol Vet. 1964;1:7.

244 Todd JD, Volenec FM, Paton IM. Interferon in nasal secretions and sera of calves after intranasal administration of a virulent infectious bovine rhinotracheitis virus: association of interferon in nasal secretions with early resistance to challenge with virulent virus. Infect Immun. 1972;5:699.

245 Todd JD, Volenec FM, Paton IM. Intranasal vaccination against infectious bovine rhinotracheitis: studies on early onset of protection and use of the vaccine in pregnant cows. Am J Vet Med Assoc. 1971;159:1370.

246 Kucera CJ, White RG, Beckenhauer WH. Evaluation of the safety and efficacy of an intranasal vaccine containing a temperature-sensitive strain of infectious bovine rhinotracheitis virus. Am J Vet Res. 1978;39:607.

247 Todd JD. Intranasal vaccination of cattle against IBR and PI-3: field and laboratory observations in dairy, beef, and neonatal populations. Dev Biol Stand. 1976;33:391.

248 Baker JC, Rust SR, Walker RD. Transmission of a vaccinal strain of infectious bovine rhinotracheitis virus from intranasally vaccinated steers commingled with nonvaccinated steers. Am J Vet Res. 1989;50:814.

249 Talens LT, Beckenhauer WH, Thurber ET, et al. Efficacy of viral components of a nonabortigenic combination vaccine for prevention of respiratory and reproductive system diseases in cattle. J Am Vet Med Assoc. 1989;194:1273.

250 Cravens RL, Ellsworth MA, Sorensen CD, White AK. Efficacy of a temperature-sensitive, modified live bovine herpesvirus type 1 vaccine against abortion and stillbirth in pregnant heifers. J Am Vet Med Assoc. 1996;208:2031.

251 Chiang BC, Smith PC, Nusbaum KE, Stringfellow DA. The effect of infectious bovine rhinotracheitis vaccine on reproductive efficiency in cattle vaccinated during estrus. Theriogenology. 1990;33:1113.

252 Miller JM, Van Der Maaten MJ, Whetstone CA. Infertility in heifers inoculated with modified live infectious bovine rhinotracheitis on postbreeding day 14. Am J Vet Res. 1989;50:551.

253 Kelling CL, Schipper IA, Strum GE, et al. Infectious bovine rhinotracheitis (IBR) abortion: observations on incidence in vaccinated and nonvaccinated and exposed cattle. Cornell Vet. 1973;63:383.

254 Gatewood DM, et al. Evaluation of IBR vaccine virus shedding after parenteral administration to suckling calves. Proceedings of the Twenty-Ninth Annual Convention of the American Association of Bovine Practitioners. 1996:178.

255 Roth JA, Vaughn MB. Evaluation of viral shedding and immune response following vaccination with a modified live BHV-1 vaccine. Bovine Pract. 1998;32:1.

256 Kleiboeker SB, Lee SM, Jones CA, Estes DM. Evaluation of shedding of bovine herpesvirus 1, bovine viral diarrhea virus 1 and bovine viral diarrhea virus 2 after vaccination of calves with a multivalent modified-live virus vaccine. J Am Vet Med Assoc. 2003;222:1399.

257 Kahrs RF. Infectious bovine rhinotracheitis. In: Viral Diseases of Cattle. Ames, Iowa: Iowa State University Press; 1981.

258 Savan M, Angulo AB, Derbyshire JB. Interferon, antibody responses, and protection induced by an intranasal infectious bovine rhinotracheitis vaccine. Can Vet J. 1979;20:207.

259 Sibbel RL, Bass EP, Thomas PC. How long will a killed IBR vaccine protect against challenge? Vet Med. 1988;83:90.

260 Trueblood MS, Swift BL, McHolland-Raymond LE. An outbreak of infectious pustular vulvovaginitis. Vet Med Small Anim Clin. 1977;72:1622.

261 Van Drunen Little-van den Hurk S. Rationale and perspectives on the success of vaccination against bovine herpesvirus-1. Vet Microbiol. 2006;113:275.

262 Henderson LM. Overview of marker vaccine and differential diagnostic test technology. Biologicals. 2005;33:203.

263 Hollis LC, Smith JF, Johnson BJ, et al. A comparison of serological responses when modified live infectious bovine rhinotracheitis virus vaccine, Mannheimia haemolytica bacterin-toxoid and Leptospira pomona bacterin are administered with needle-free versus conventional needle-based injection in yearling feedlot steers. Bovine Pract. 2005;39:106.

264 Hollis LC, Smith JF, Johnson BJ, et al. A comparison of serological responses when modified live infectious bovine rhinotracheitis virus vaccine, Mannheimia haemolytica bacterin-toxoid and Leptospira pomona bacterin are administered with needle-free versus conventional needle-based injection in Holstein dairy calves. Bovine Pract. 2005;39:110.

265 Perino LJ, Hunsaker BD. A review of bovine respiratory disease vaccine field efficacy. Bovine Pract. 1997;31:59.

266 Gregersen JP, Wagner K. Persistent infection of the genital tract and excretion of the vaccine strain after live virus immunization with bovine herpesvirus 1 (IBR/IPV virus). Zentralbl Veterinarmed B. 1985;32:354.

267 Schultz RD, et al. Current status of IBR-IPV infection in bulls. Proc U S Anim Health Assoc. 1976;80:159.

268 Roth JA. Building immunity. National Hog Farmer. 1992:1. Spring

269 Van Donkersgoed J, van den Hurk JV, McCartney D, Harland RJ. Comparative serological responses in calves to eight commercial vaccines against infectious bovine rhinotracheitis, parainfluenza-3, bovine respiratory syncytial, and bovine viral diarrhea viruses. Can Vet J. 1991;32:727.

270 Heuschele WP. Bovine virus diarrhea mucosal disease. In: Howard JL, editor. Current veterinary therapy (food animal practice) 2. Philadelphia: Saunders, 1986.

271 Baker JC. Bovine viral diarrhea: a review. J Am Vet Med Assoc. 1987;190:1449.

272 Cortese VS, Whittaker R, Ellis J, et al. Specificity and duration of neutralizing antibodies induced in healthy cattle after administration of a modified live virus vaccine against bovine viral diarrhea virus. Am J Vet Res. 1998;59:848.

273 Roth JA, Kaeberle ML. Suppression of neutrophil and lymphocyte function induced by a vaccinal strain of bovine viral diarrhea virus, with or without the administration of ACTH. Am J Vet Res. 1983;44:2366.

274 Rosner SF. Complications following vaccination of cattle against bovine rhinotracheitis, bovine viral diarrhea—mucosal disease and parainfluenza type 3. J Am Vet Med Assoc. 1968;152:898.

275 Bolin SR, Ridpath JF. Delayed onset postvaccinal mucosal disease as a result of genetic recombination between genotype 1 and genotype 2 BVDV. Virology. 1995;212:259.

276 Bolin SR, Littledike ET, Ridpath JF. Serologic detection and practical consequences of antigenic diversity among bovine viral diarrhea viruses in a vaccinated herd. Am J Vet Res. 1991;52:1033.

277 Bolin SR, Ridpath JF. Specificity of neutralizing and precipitating antibodies induced in healthy calves by monovalent modified live bovine viral diarrhea virus vaccines. Am J Vet Res. 1989;50:817.

278 BoviShield FP 5 label, Pfizer Animal Health, New York, New York

279 Cortese VS, West KH, Hassard LE, et al. Clinical and immunologic responses of vaccinated and unvaccinated calves to infection with a virulent type II isolate of bovine viral diarrhea virus. J Am Vet Med Assoc. 1998;213:1312.

280 Dean HJ, Leyh R. Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine. 1998;17:1117.

281 Cortese VS. Clinical and immunologic responses of cattle to vaccinal and natural bovine viral diarrhea virus (BVDV) [thesis]. Western College of Veterinary Medicine, University of Saskatchewan, 1998.

282 Fulton RW, Briggs RE, Ridpath JF, et al. Transmission of bovine viral diarrhea virus lb to susceptible and vaccinated calves by exposure to persistently infected calves. Can J Vet Res. 2005;69:161.

283 Bolin SR. The current understanding about the pathogenesis and clinical forms of BVD: symposium on bovine viral diarrhea. Vet Med. 1990;85:1124.

284 Moennig V, Frey HR, Liebler E, et al. Reproduction of mucosal disease with a cytopathogenic bovine viral diarrhea virus selected in vitro. Vet Rec. 1990;127:200.

285 Bolin SR, McClurkin AW, Cutlip RC, Coria MF. Response of cattle persistently infected with noncytopathic bovine viral diarrhea virus to vaccination for bovine viral diarrhea and to subsequent challenge exposure with cytopathic bovine viral diarrhea virus. Am J Vet Res. 1985;46:2467.

286 Meyling A, et al. Experimental exposure of vaccinated and nonvaccinated pregnant cattle to isolates of bovine viral diarrhea virus (BVDV). Slate Veterinary Institute for Virus Research. 1985:225.

287 McClurkin AW, Coria MF, Smith RL. Evaluation of acetylethylenimine-killed bovine viral diarrhea—mucousal disease virus vaccine for prevention of BVD infection of the fetus. Proc US Anim Health Assoc. 1975;79:115.

288 Kaeberle ML, Maxwell D, Johnson E. Efficacy of inactivated bovine viral diarrhea virus vaccines in a cow herd. 1990 Beef/Sheep report A.S.. 1990;701:42. Leaflet R

289 Ellsworth MA, et al. Fetal infection following intravenous bovine viral diarrhea virus challenge of vaccinated and unvaccinated dams. Proceedings of the Conference of Research Workers in Animal Disease. 1994.

290 Harkness JW, Roeder PL, Drew T. The efficacy of an experimental inactivated BVD-MD vaccine. Harkness JW, editor. Pestivirus infections in ruminants: a seminar in the CEC programme of coordination of research on animal husbandry. 1985. Brussels, Sept 10–11, 1985

291 Brownlie J, Clarke MC, Hooper LB, Bell GD. Protection of the bovine fetus from bovine viral diarrhea virus by means of a new inactivated vaccine. Vet Rec. 1995;137:58.

292 Frey HR, Eicken K. Undersuchungen uber die Wirksamkeit einer inaktivierten BVD-Vakzine zur Erhohung der Sicherheit einer BVD-Lebendvakzine. Tierarztl Umschan. 1995;50:86.

293 Cortese VS, et al. Protection of pregnant cattle and their fetuses against infection with bovine viral diarrhea virus type 1 by use of a modified live virus vaccine. Am J Vet Res. 1999;59:1409.

294 Fairbanks KK, Rinehart CL, Ohnesorge WC, et al. Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. J Am Vet Med Assoc. 2004;225:1898.

295 Brock KV, Cortese VS. Experimental fetal challenge using type II bovine viral diarrhea virus in cattle vaccinated with modified-live virus vaccine. Vet Ther. 2001;2:354.

296 Ficken M, Ellswort MA, Tucker CM, Cortese VS. Effects of modified-live bovine viral diarrhea virus vaccines containing either type I or types I and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation. J Am Vet Med Assoc. 2006;228:1559.

297 Kendrick JW, Franti CE. Bovine viral diarrhea: decay of colostrum derived antibody in the calf. Am J Vet Res. 1974;35:589.

298 Ernst PB, Butler DG. A bovine viral diarrhea calfhood vaccination trial in a persistently infected herd: effects on titers, health, and growth. Can J Comp Med. 1983;47:118.

299 Kaeberle ML, Sealock R, Honeyman M. Antibody responses of young calves to inactivated viral vaccines, AS Leaflet R. 1997 Beef/Sheep Rep. 1990;1462:42.

300 Brar JS, et al. Maternal immunity to infectious bovine rhinotracheitis and bovine viral diarrhea viruses: duration and effect on vaccination in young calves. Am J Vet Res. 1978;39:241.

301 Kelling CL, Stine LC, Rump KK, et al. Investigation of bovine viral diarrhea virus infections in a range beef cattle herd. J Am Vet Med Assoc. 1990;197:589.

302 Sanders DE, Sanders JA, Sangenario J. Protection of newborn calves against bovine virus diarrhea by vaccinating their dams before parturition. Agri-Practice. 1983;10:30.

303 Orban S, Liess B, Hafez SM, et al. Studies on transplacental transmissibility of a bovine virus diarrhea (BVD) vaccine virus. I. Inoculation of pregnant cows 15 to 90 days before parturition (190th to 265th day of gestation). Zentralbl Veterinarmed B. 1983;30:619.

304 Liess B, Orban S, Frey HR, et al. Studies on transplacental transmissibility of a bovine virus diarrhea (BVD) vaccine virus in cattle. II. Inoculation of pregnant cows without detectable neutralizing antibodies to BVD virus 90–229 days before parturition (51st to 190th day of gestation). Zentralbl Veterinarmed B. 1984;31:669.

305 Ames TR, Baker JC. Management practices and vaccination programs that help control BVD virus infections: symposium on bovine viral diarrhea. Vet Med. 1990:1140. October:

306 Van der Poel WH, Brand A, Kramps JA, Van Oirschot JT. Respiratory syncytial virus infections in human beings and in cattle. J Infect. 1994;29:215.

307 Baker JC, Ellis JA, Clark EG. Bovine respiratory syncytial virus. Vet Clin North Am Food Anim Pract. 1997;13:425.

308 Kimman TG, Westenbrink F. Immunity to human and bovine respiratory syncytial virus. Arch Virol. 1990;112:1.

309 Bryson DG, McNulty MS, Logan EF, Cush PF. Respiratory syncytial virus pneumonia in young calves: clinical and pathologic findings. Am J Vet Res. 1983;44:1648.

310 Bryson DG. Necropsy findings associated with BRSV pneumonia. Vet Med. 1993;88:6.

311 Kimman TG, Straver PJ, Zimmer GM. Pathogenesis of naturally acquired bovine respiratory syncytial virus infection in calves: morphologic and serologic findings. Am J Vet Res. 1989;50:684.

312 Ferguson JD, Galligan DT, Cortese V. Milk production and reproductive performance in dairy cows given bovine respiratory syncytial virus vaccine prior to parturition. J Am Vet Med Assoc. 1997;210:1779.

313 West K, Petrie L, Konoby C, et al. The efficacy of modified live bovine respiratory syncytial virus vaccines in experimentally infected calves. Vaccine. 1999;18:907.

314 Ellis JA, Hassard LE, Cortese VS, Morley PS. The effect of perinatal vaccination on humoral and cellular immune responses in cows and young calves. J Am Vet Med Assoc. 1996;208:393.

315 Ellis J, West K, Konoby C, et al. Efficacy of an inactivated respiratory syncytial virus vaccine in calves. J Am Vet Med Assoc. 2001;218:1973.

316 Ellis JA, West KH, Waldner C, Rhodes C. Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J. 2005;46:155.

317 Hägglund S, Hu KF, Larsen LE, et al. Bovine respiratory syncytial virus ISCOMs—protection in the presence of maternal antibodies. Vaccine. 2004;23:646.

318 Patel J, Didlick S. Evaluation of efficacy of an inactivated vaccine against bovine respiratory syncytial virus in calves with maternal antibodies. Am J Vet Res. 2004;65:417.

319 Van Donkersgoed J, Janzen ED, Townsend HG, Durham PJ. Five field trials on the efficacy of a bovine respiratory syncytial virus vaccine. Can Vet J. 1990;31:93.

320 Hansen DE, Syvrud R, Armstrong D. Effectiveness of a respiratory syncytial virus vaccine in reducing the risk of respiratory disease. Agri-Practice. 1992;13:19.

321 Kimman TG, Zimmer GM, Westenbrink F, et al. Epidemiologic study of bovine respiratory syncytial virus infection in calves: influence of maternal antibodies on the outcome of disease. Vet Rec. 1988;123:104.

322 Belknap EB, Baker JC, Patterson JS, et al. The role of passive immunity in bovine respiratory syncytial virus infected calves. J Infect Dis. 1991;163:470.

323 Baker JC, Ames TR, Markham RJF. A seroepidemiologic study of bovine respiratory syncytial virus in a dairy herd. Am J Vet Res. 1986;47:240.

324 Kimman TG, Westenbrink F, Schreuder BE, Straver PJ. Local and systemic antibody response to bovine respiratory syncytial virus infection in calves with or without maternal antibodies. J Clin Microbiol. 1987;25:1097.

325 Woolums AR, Brown CC, Brown JCJr, et al. Effect of a single intranasal dose of modified-live bovine respiratory syncytial virus vaccine on resistance to subsequent viral challenge in calves. Am J Vet Res. 2004;65:363.

326 Vangeel I, et al. Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in three-week old calves experimentally challenged with BRSV. Br Cattle Vet Assoc. 2005;13:263.

327 Ellis J, Gow S, West K, et al. Response of calves to challenge exposure with virulent BRSV following intranasal administration of parenteral vaccines. J Am Vet Med Assoc. 2007;230:233.

328 Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422.

329 Gershwin LJ, Schelegle ES, Gunther RA, et al. A bovine model of vaccine-enhanced respiratory syncytial virus pathophysiology. Vaccine. 1998;16:1225.

330 Antonis AF, Schrijver RS, Daus F, et al. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. J Virol. 2003;77:12067.

331 Kimman TG, Sol J, Westenbrink F, Straver PJ. A severe outbreak of respiratory tract disease associated with bovine respiratory syncytial virus probably enhanced by vaccination with modified live vaccine. Vet Q. 1989;11:250.

332 Schreiber P, Matheise JP, Dessy F, et al. High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian blue calves previously vaccinated with an inactivated vaccine. J Vet Med B Infect Dis Vet Public Health. 2000;47:535.

333 Ellis JA, Hassard LE, Morley PS. Bovine respiratory syncytial virus—specific immune responses in calves after inoculation with commercially available vaccines. J Am Vet Med Assoc. 1995;206:354.

334 West K, Ellis J. Functional analysis of antibody responses of feedlot cattle to bovine respiratory syncytial virus following vaccination with mixed vaccines. Can J Vet Res. 1997;62:245.

335 West K, Petrie L, Haines DM, et al. The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection of calves. Vaccine. 1999;17:809.

336 Kapil S, Basaraba R. Infectious bovine rhinotracheitis, parainfluenza-3, and respiratory coronavirus. Vet Clin North Am. 1997;13:455.

337 Graham DA, McShane J, Mawhinney KA, et al. Evaluation of a single dilution ELISA system for detection of seroconversion to bovine viral diarrhoea virus, bovine respiratory syncytial virus, parainfluenza-3 virus and infectious bovine rhinotracheitis virus: comparison with testing by virus neutralisation and haemagglutination inhibition. J Vet Diagn Invest. 1998;10:43.

338 Bryson DG, Adair BM, McNulty MS, et al. Studies on the efficacy of intranasal vaccination for prevention of experimentally induced parainfluenza type 3 virus pneumonia in calves. Vet Rec. 1999;145:33.

339 Gates GA, Cesario TC, Ebert JW, et al. Neutralizing antibody in experimentally induced respiratory infection in calves. Am J Vet Res. 1970;31:217.

340 Gutekunst DE, Paton IM, Volenec FJ. Parainfluenza-3 vaccine in cattle: comparative efficacy of intranasal and intramuscular routes. J Am Vet Med Assoc. 1969;155:1879.

341 McKercher DG, Saito JK, Franti CE, et al. Response of calves to parainfluenza-3 vaccines administered nasally or parenterally. Am J Vet Res. 1972;33:721.

342 Sweat RL. Epizootiologic studies of bovine myxovirus parainfluenza-3. J Am Vet Med Assoc. 1967;150:178.

343 Ferguson JD, Galligan DT, Cortese V. Milk production and reproductive performance in dairy cows given bovine respiratory syncytial virus vaccine prior to parturition. J Am Vet Med Assoc. 1997;210:1779.

344 Woods GT, Mansfield ME, Webb RJ. A 3-year comparison of acute respiratory disease, shrink, and weight gain in preconditioned and nonconditioned Illinois beef calves sold at the same auction and mixed in a feedlot. Can J Comp Med. 1973;37:249.

345 Bingham HR, Morley PS, Wittum TE, et al. Synergistic effects of concurrent challenge with bovine respiratory syncytial virus and 3-methylindole in calves. Am J Vet Res. 1999;60:563.

346 Schunicht OC, Booker CW, Jim GK, et al. Comparison of a multivalent viral vaccine program versus a univalent vaccine program on animal health, feedlot performance, and carcass characteristics of feedlot calves. Can Vet J. 2003;44:43.

347 Welsh RD. Bacterial and Mycoplasma species isolated from pneumonic bovine lungs. Agri-Practice. 1993;14:12.

348 Welsh RD, Dye LB, Payton ME, Confer AW. Frequency of isolation and antimicrobial susceptibilities of bacterial pathogens from bovine pneumonia: 1994–2002. J Vet Diag Invest. 2004;16:426.

349 Angen O, Mutters R, Caugant DA, et al. Taxonomic relationships of the [Pasteurella] haemolytica complex as evaluated by DNA-DNA hybridizations and 16S rRNA sequencing with proposal of Mannheimia haemolytica gen. nov., comb. nov., Mannheimia granulomatis comb. nov., Mannheimia glucosida sp. nov., Mannheimia ruminalis sp. nov. and Mannheimia varigena sp. nov. Int J Syst Bacteriol. 1999;49(Pt 1):67.

350 Confer AW. Immunogens of Pasteurella. Vet Microbiol. 1993;37:353.

351 Lee CW, Shewen PE. Evidence of bovine immunoglobulin G1 (IgG1) protease activity in partially purified culture supernate of Pasteurella haemolytica A1. Can J Vet Res. 1996;60:127.

352 Shewen PE, Wilkie BN. Vaccination of calves with leukotoxic culture supernatant from Pasteurella haemolytica. Can J Vet Res. 1988;52:30.

353 Confer AW, Ayalew S, Montelongo M, et al. Immunogenicity of Mannheimia haemolytica serotype 1 recombinant outer membrane protein PlpE and augmentation of a commercial vaccine. Vaccine. 2003;21:2821.

354 Confer AW, Ayalew S, Panciera RJ, et al. Recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE enhances commercial M. haemolytica vaccine-induced resistance against serotype 6 challenge. Vaccine. 2006;24:2248.

355 Confer AW, McCraw RD, Durham JA, et al. Serum antibody responses of cattle to iron-regulated outer membrane proteins of Pasteurella haemolytica A1. Vet Immunol Immunopathol. 1995;47:101.

356 Morton RJ, Panciera RJ, Fulton RW, et al. Vaccination of cattle with outer membrane protein-enriched fractions of Pasteurella haemolytica and resistance against experimental challenge. Am J Vet Res. 1995;56:875.

357 Potter AA, Schryvers AB, Ogunnariwo JA, et al. Protective capacity of the Pasteurella haemolytica transferrin-binding proteins TbpA and TbpB in cattle. Microb Pathog. 1999;27:197.

358 Chae CH, Gentry MJ, Confer AW, Anderson GA. Resistance to host immune defense mechanisms afforded by capsular material of Pasteurella haemolytica, serotype 1. Vet Microbiol. 1990;25:241.

359 Confer AW, Simons KR, Panciera RJ, et al. Serum antibody response to carbohydrate antigens of Pasteurella haemolytica serotype 1: relation to experimental bovine pneumonic pasteurellosis. Am J Vet Res. 1989;50:98.

360 Conlon JSR, Shewen PE. Clinical and serological evaluation of a Pasteurella haemolytica A1 capsular polysaccharide. Vaccine. 1993;11:767.

361 Confer AW, Panciera RJ, Mosier DA. Serum antibodies to Pasteurella haemolytica lipopolysaccharide: relationship to experimental bovine pneumonic pasteurellosis. Am J Vet Res. 1986;47:1134.

362 Mosier DA, Simons KR, Vestweber JG. Passive protection of calves with Pasteurella haemolytica antiserum. Am J Vet Res. 1995;56:1317.

363 ed 5. Arrioja-Dechert A, editor. Compendium of veterinary products. Port Huron, Mich: North American Compendiums; 1999.

364 Roth JA, Perino LJ. Immunology and prevention of infection in feedlot cattle. Vet Clin North Am Food Anim Pract. 1998;14:233.

365 Confer AW, Panciera RJ, Gentry MJ, Fulton RW. Immunological response to Pasteurella haemolytica and resistance against experimental bovine pneumonic pasteurellosis, induced by bacterins in oil adjuvants. Am J Vet Res. 1987;48:163.

366 Confer AW, Panciera RJ. Testing of two new generation Pasteurella haemolytica vaccines against experimental bovine pneumonic pasteurellosis. Agri-Practice. 1994;15:10.

367 Mosier DA, Panciera RJ, Rogers DP, et al. Comparison of serologic and protective responses induced by two Pasteurella vaccines. Can J Vet Res. 1998;62:178.

368 Srinand S, Hsuan SL, Yoo HS, et al. Comparative evaluation of antibodies induced by commercial Pasteurella haemolytica vaccines using solid phase immunoassays. Vet Microbiol. 1996;49:181.

369 Prado ME, Confer AW, Prado TM. Maternally and naturally acquired antibodies to Mannheimia haemolytica and Pasteurella multocida in beef calves. Vet Immunol Immunopathol. 2006;111:301.

370 Shewen PE, Lee CW, Perets A, et al. Efficacy of recombinant sialoglycoprotease in protection of cattle against pneumonic challenge with Mannheimia (Pasteurella) haemolytica A1. Vaccine. 2003;21:1901.

371 Frank GH, Briggs RE, Loan RW, et al. Respiratory tract disease and mucosal colonization by Pasteurella haemolytica in transported cattle. Am J Vet Res. 1996;57:1317.

372 Smith RA, Deyhle C, Engler M, et al. Pasteurella haemolytica pneumonia, part 1. Agri-Practice. 1994;15:5.

373 Smith RA, Deyhle C, Engler M, et al. Pasteurella haemolytica pneumonia, part 2. Agri-Practice. 1994;15:21.

374 Smith RA, Deyhle C, Engler M, et al. Pasteurella haemolytica pneumonia, part 3. Agri-Practice. 1994;15:41.

375 Shewen PE. Host response to infection with HAP: implications for vaccine development. In: Donachie W, Lainson FA, Hodgson JC, editors. Haemophilus, Actinobacillus and Pasteurella. London: Plenum; 1995:165.

376 Confer AW, Montelongo M, Brown MJ, et al. Onset of serum antibodies to Pasteurella (Mannheimia) haemolytica following vaccination with five commercial vaccines. Bovine Pract. 2001;35:141.

377 Confer AW, Fulton RW, Clinkenbeard KD, Driskel BA. Duration of serum antibody responses following vaccination and revaccination of cattle with non-living commercial Pasteurella haemolytica vaccines. Vaccine. 1998;16:1962.

378 Perino LJ, Hunsaker BD. A review of bovine respiratory disease vaccine field efficacy. Bovine Pract. 1997;31:59.

379 Bechtol DT, Ballinger RT. Field trial of a Pasteurella haemolytica toxoid administered at spring branding and in the feedlot. Agri-Practice. 1991;12:6.

380 Stephens LR, Little PB, Wilkie BN, et al. Isolation of Haemophilus somnus antigens and their use as vaccines for prevention of bovine thromboembolic meningoencephalitis. Am J Vet Res. 1984;45:234.

381 Hodgins DC, Shewen PE. Serologic responses of young colostrum fed dairy calves to antigens of Pasteurella haemolytica A1. Vaccine. 1998;16:2018.

382 Aubry P, Warnick LD, Guard CL, et al. Health and performance of young dairy calves vaccinated with a modified-live Mannheimia haemolytica and Pasteurella multocida vaccine. J Am Vet Med Assoc. 2001;219:1739.

383 Stevens RD, Dinsmore RP, Ellis RP, Katsampas M. Morbidity and mortality in young Holstein heifer calves vaccinated with an M. haemolytica leukotoxoid. Large Anim Pract. 1997;18:23.

384 Schnepper RL, Srinand S, Maheswaran SK, Jones GF. Respiratory morbidity in veal calves given Pasteurella vaccines. Vet Med. 1996;91:72.

385 Verma R, Jaiswal TN. Haemorrhagic septicaemia vaccines. Vaccine. 1998;16:1184.

386 Prado ME, Dabo SM, Confer AW. Immunogenicity of iron-regulated outer membrane proteins of Pasteurella multocida A:3 in cattle: molecular characterization of the immunodominant heme acquisition system receptor (HasR) protein. Vet Microbiol. 2005;105:269.

387 Confer AW, Nutt SH, Dabo SM, et al. Antibody responses of cattle to outer membrane proteins of Pasteurella multocida A:3. Am J Vet Res. 1996;57:1453.

388 Inzana TJ, Hensley J, McQuiston J, et al. Phase variation and conservation of lipooligosaccharide epitopes in Haemophilus somnus. Infect Immun. 1997;65:4675.

389 Corbeil LB, Bastida-Corcuera FD, Beveridge TJ. Haemophilus somnus immunoglobulin binding proteins and surface fibrils. Infect Immun. 1997;65:4250.

390 Yu RH, Gray-Owen SD, Ogunnariwo J, Schryvers AB. Interaction of ruminant transferrins with transferrin receptors in bovine isolates of Pasteurella haemolytica and Haemophilus somnus. Infect Immun. 1992;60:2992.

391 Confer AW, Fulton RW. Evaluation of Pasteurella and Haemophilus vaccines. Bovine Proc. 1995;27:136.

392 Tagawa Y, Bastida-Corcuera F, Corbeil LB. Immunological characterization of the major outer membrane protein of Haemophilus somnus. Vet Microbiol. 2000;71:245.

393 Stephens LR, Little PB, Humphrey JD, et al. Vaccination of cattle against experimentally induced thromboembolic meningoencephalitis with a Haemophilus somnus bacterin. Am J Vet Res. 1982;43:1339.

394 Groom SC, Little PB. Effects of vaccination of calves against induced Haemophilus somnus pneumonia. Am J Vet Res. 1988;49:793.

395 Martin SW, Harland RJ, Bateman KG, Nagy E. The association of titers to Haemophilus somnus, and other putative pathogens, with the occurrence of bovine respiratory disease and weight gain in feedlot calves. Can J Vet Res. 1998;62:262.

396 Ruby KW, Griffith RW, Gershwin LJ, Kaeberle ML. Haemophilus somnus—induced IgE in calves vaccinated with commercial monovalent H. somnus bacterins. Vet Microbiol. 2000;76:373.

397 Amstutz HE, Horstman LA, Morter RL. Clinical evaluation of the efficacy of Haemophilus somnus and Pasteurella species bacterins. Bovine Pract. 1981;16:106.

398 Morter RL, Amstutz HE Evaluating the efficacy of a Haemophilus somnus bacterin in a controlled field trial. Bovine Pract. 1983;18:82.

399 Van Donkersgoed J, Schumann FJ, Harland RJ, et al. The effect of route and dosage of immunization on the serological response to a Pasteurella haemolytica and Haemophilus somnus vaccine in feedlot cattle. Can Vet J. 1993;34:731.

400 Morter RL, Amstutz HE, Crandell RA. Clinical evaluation of prophylactic regimens for bovine respiratory disease. Bovine Pract. 1982;17:56.

401 O’Connor A, Martin SW, Harland R, et al. The relationship between the occurrence of undifferentiated bovine respiratory disease and titer changes to Haemophilus somnus and Mannheimia haemolytica at 3 Ontario feedlots. Can J Vet Res. 2001;65:143.

402 Ribble CS, Jim GK, Janzen ED. Efficacy of immunization of feedlot calves with a commercial Haemophilus somnus vaccine. Can J Vet Res. 1988;52:191.

403 Lambert G, Deyoe BL, Painter GM. Postvaccinal persistence of Brucella abortus strain 19 in two bulls. J Am Vet Med Assoc. 1964;145:909.

404 Roberts SJ, Squire RA, Gilman HL. Deaths in two calves following vaccination with Brucella abortus strain 19 vaccine. Cornell Vet. 1962;52:592.

405 Nicoletti P. Brucellosis. In: Howard JL, editor. Current veterinary therapy: food animal practice 2. Philadelphia: Saunders, 1986.

406 Confer AW, Hall SM, Faulkner CB, et al. Effect of challenge dose on the clinical and immune responses of cattle vaccinated with reduced doses of Brucella abortus strain 19. Vet Microbiol. 1985;10:561.

407 Blood DC, Radostitis OM, Henderson JA. Veterinary medicine, ed 6. London: Baillière Tindall; 1983.

408 Brenner DJ, Kaufmann AF, Sulzer KR, et al. Further determination of DNA relatedness between serogroups and serovars in the family Leptospiraceae with a proposal for Leptospira alexanderi sp. nov. and 4 new Leptospira genomospecies. Int J Syst Bacteriol. 1999;49:839.

409 White FH, Sulzer KR, Engle RW. Isolation of Leptospira interrogans serovars Hardjo, Balcanica, and Pomona from cattle at slaughter. Am J Vet Res. 1982;43:1172.

410 Ellis WA, Thiermann AB. Isolation of Leptospira from the genital tract of Iowa cows at slaughter. Am J Vet Res. 1986;47:1649.

411 Talpada MD, Garvey N, Sprowls R, et al. Prevalence of leptospiral infection in Texas cattle: implications for transmission to humans. Vector Borne Zoonotic Dis. 2003;3:141.

412 Miller DA, Wilson MA, Beran GW. Survey to estimate prevalence of Leptospira interrogans infection in mature cattle in the United States. Am J Vet Res. 1991;52:1761.

413 Thiermann AB. Experimental leptospiral infections in pregnant cattle with organisms of Hebdomadia serogroup. Am J Vet Res. 1982;43:78.

414 Ellis WA, Songer JG, Montgomery J, et al. Prevalence of Leptospira interrogans serovar Hardjo in the genital and urinary tracts of non-pregnant cattle. Vet Rec. 1986;118:11.

415 Ellis WA. Effects of leptospirosis on bovine reproduction. In: Morrow DA, editor. Current therapy in theriogenology 2. Philadelphia: Saunders, 1986.

416 Ellis WA, Thiermann AB, Marshall RB. Genotypes of Leptospira interrogans serovar hardjo and their role in clinical disease. Proc 14th World Congr Dis Cattle. 1986;2:966.

417 Hanson LE. Effects of leptospirosis on bovine reproduction. In: Morrow DA, editor. Current therapy in theriogenology. Philadelphia: Saunders, 1980.

418 Faine S, Adler B, Bolin CA, et al. Leptospira and leptospirosis, ed 2. Melbourne: MediSci Press; 1999.

419 Bey RF, Johnson RC. Current status of leptospiral vaccines. Prog Vet Microbiol Immunol. 1986;2:175.

420 Kiesel GK, Dacres WG. A study of Leptospira pomona bacterin in cattle. Cornell Vet. 1959;49:332.

421 Hanson LE, Tripathy DN, Killinger AH. Current status of leptospirosis immunization in swine and cattle. J Am Vet Med Assoc. 1972;161:1235.

422 Bolin CA, Thiermann AB, Handsaker AL, et al. Effect of vaccination with a pentavalent leptospiral vaccine on Leptospira interrogans serovar Hardjo type hardjo-bovis infection of pregnant cattle. Am J Vet Res. 1989;50:161.

423 Bolin CA, Zuerner RL, Trueba G. Effect of vaccination with a pentavalent leptospiral vaccine containing Leptospira interrogans serovar Hardjo type hardjo-bovis on type hardjo-bovis infection of cattle. Am J Vet Res. 1989;50:2004.

424 Bolin CA, Cassells JA, Zuerner RL, et al. Effect of vaccination with a monovalent Leptospira interrogans serovar Hardjo type hardjo-bovis vaccine on type hardjo-bovis infection of cattle. Am J Vet Res. 1991;52:1639.

425 Bolin CA, Alt DP. Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar hardjo. Am J Vet Res. 2001;62:995.

426 Ellis WA, McDowell SWJ, Mackie DP, et al. Immunity to bovine leptospirosis. Proceedings of the 21st World Buiatrics Congress, Punte del Este, Uruguay. 2000.

427 Naiman B, Alt DP, Bolin CA, et al. Protective killed Leptospira vaccine induces a potent Th1 immune response comprised of CD4 and γδ T lymphocytes in cattle. Infect Immun. 2001;65:7550.

428 Naiman BM, Blumerman S, Alt DP, et al. Evaluation of type 1 immune response in naive and vaccinated animals following challenge with Leptospira borgpetersenii serovar Hardjo: involvement of WC1(+) gammadelta and CD4 T cells. Infect Immun. 2002;70:6147.

429 Brown RA, Blumerman S, Gay C, et al. Comparison of type 1 immune responses to Leptospira borgpetersenii serovar Hardjo induced by three different leptospiral vaccines. Vaccine. 2003;21:4448.

430 Bolin CA., Alt DP, Zuerner RL. Protection of cattle from renal and genital tract colonization with Leptospira borgpetersenii serovar Hardjo. Proceedings of the 21st World Buiatrics Congress, Punte del Este, Uruguay. 2000.

431 Ellis WA, Cassells JA, Doyle J. Genital leptospirosis in bulls. Vet Rec. 118, 1986.

432 DeKeyser PJ. Bovine genital campylobacteriosis. In: Morrow DA, editor. Current theriogenology 2. London: Saunders, 1986.

433 Bouters R, De Keyser J, Vandeplassche M, et al. Vibrio fetus infection in bulls: curative and preventive vaccination. Br Vet J. 1973;129:52.

434 Clark BL, et al. Studies on venereal transmission of Campylobacter fetus by immunized bulls. Aust Vet J. 1975;51:531.

435 Clark BL, Dufty JH, Monsbourgh MJ, Parsonson IM. A dual vaccine for immunization of bulls against vibriosis. Aust Vet J. 1979;55:43.

436 Hoerlein AB. Vibriosis. In: Morrow DA, editor. Current therapy in theriogenology 2. Philadelphia: Saunders, 1986.

437 Dawson LJ. Diagnosis, prevention and control of campylobacteriosis and trichomoniasis. Bovine Pract. 1986;21:180.

438 Hoerlein AB, Carroll EJ. Duration of immunity to bovine genital vibriosis. J Am Vet Med Assoc. 1970;156:775.

439 Berg RL, Firehammer BD. Effect of interval between booster vaccination and time of breeding on protection against campylobacteriosis (vibriosis) in cattle. J Am Vet Med Assoc. 1978;173:467.

440 Kimsey PB. Bovine trichomoniasis. In: Morrow DA, editor. Current therapy in theriogenology 2. Philadelphia: Saunders, 1986.

441 Bartlett DE. Trichomonas foetus infection and bovine reproduction. Am J Vet Res. 1947;8:343.

442 Parsonson IM, Clark BI, Duffy JH. Early pathogenesis and pathology of Tritrichomonas foetus infection in virgin heifers. J Comp Pathol. 1976;86:59.

443 Kendrick JW. An outbreak of bovine trichomoniasis in a group of bulls used for artificial insemination. Cornell Vet. 1953;43:231.

444 Perino LJ, Rupp GP. Beef cow immunity and its influence on fetal neonatal calf health. Proceedings of the Twenty-Eighth Annual Convention of the American Association of Bovine Practitioners. 1995:145.

445 Ikeda JS, BonDurant RH, Campero CM, Corbeil LB. Conservation of a protective surface antigen of Tritrichomonas foetus. J Clin Microbiol. 1993;31:3289.

446 Clark BL, Duffy JH, Parsonson IM. Immunization of bulls against tritrichomoniasis. Aust Vet J. 1983;60:178.

447 Corbeil LB. Vaccination strategies against Tritrichomonas foetus. Parasitol Today. 1994;10:103.

448 Hjerpe CA: Bovine vaccines and herd vaccination programs, Vet Clin North Am. Food Anim Pract 6:171, 1990

449 Cornaglia EM, Fernandez FM, Gottschalk M, et al. Reduction in morbidity due to diarrhea in nursing beef calves by use of an inactivated oil-adjuvanted rotavirus—Escherichia coli vaccine in the dam. Vet Microbiol. 1992;30:191.

450 Holland RE. Some infectious causes of diarrhea in young farm animals. Clin Microbiol Rev. 1990;3:345.

451 Acres SD, Laing CJ, Saunders JR, et al. Acute undifferentiated neonatal diarrhea in beef calves I. Occurrence and distribution of infectious agents. Can J Comp Med. 1975;39:116.

452 Morin M, Lariviere S, Lallier R. Pathological and microbiological observations made on spontaneous cases of acute neonatal calf diarrhea. Can J Comp Med. 1976;40:228.

453 Moon HW, McClurkin AW, Isaccson RE, et al. Pathogenic relationships of rotavirus, Escherichia coli, and other agents in mixed infections in calves. J Am Vet Med Assoc. 1978;173:577.

454 McDonough SP, Stull CL, Osburn BI. Enteric pathogens in intensively reared veal calves. Am J Vet Res. 1994;55:1516.

455 Chinsangaram J, Schore CE, Guterbock W, et al. Prevalence of group A and group B rotaviruses in the feces of neonatal dairy calves from California. Comp Immun Microbiol Infect Dis. 1995;18:93.

456 de la Fuente R, Luzón M, Ruiz-Santa-Quiteria JA, et al. Cryptosporidium and concurrent infections with other major enteropathogens in 1- to 30-day-old diarrheic dairy calves in central Spain. Vet Parasitol. 1999;80:179.

457 O’Handley RM, Cockwill C, McAllister TA, et al. Duration of naturally acquired giardiosis and cryptosporidiosis in dairy calves and their association with diarrhea. Am J Vet Res. 1999;214:391.

458 Niilo L. Clostridium perfringens type C enterotoxemia. Can Vet J. 1988;29:658.

459 Tzipori SR, Makin TJ, Smith ML, et al. Clinical manifestations of diarrhea in calves infected with rotavirus and enterotoxigenic Escherichia coli. J Clin Microbiol. 1981;13:1011.

460 Sabara M, Deregt D, Babiuk LA, Misra V. Genetic heterogeneity within individual bovine rotavirus isolates. J Virol. 1982;44:813.

461 Torres-Medina A. Effect of combined rotavirus and Escherichia coli in neonatal gnotobiotic calves. Am J Vet Res. 1984;45:643.

462 Clement JC, King ME, Salman MD, et al. Use of epidemiologic principles to identify risk factors associated with the development of diarrhea in calves in five beef herds. J Am Vet Med Assoc. 1995;207:1334.

463 Rea DE, Tyler JW, Hancock DD, et al. Prediction of calf mortality by use of tests for passive transfer of colostral immunoglobulin. J Am Vet Med Assoc. 1996;208:2047.

464 Dewell RD, Hungerford LL, Keen JE, et al. Association of neonatal serum immunoglobulin G1 concentration with health and performance in beef calves. J Am Vet Med Assoc. 2006;228:914.

465 Acres SD, Babiuk LA. Studies on rotaviral antibody in bovine serum and lacteal secretions using radioimmunoassay. J Am Vet Med Assoc. 1978;173:555.

466 Schlafer DH, Scott FW. Prevalence of neutralizing antibody to the calf rotavirus in New York cattle. Cornell Vet. 1979;69:262.

467 Myers LL, Snodgrass DR. Colostral and milk antibody titers in cows vaccinated with a modified live rotavirus-coronavirus vaccine. J Am Vet Med Assoc. 1982;181:486.

468 Rodak L, Babiuk LA, Acres SD. Detection by radioimmunoassay and enzyme-linked immunosorbent assay of coronavirus antibodies in bovine serum and lacteal secretions. J Clin Microbiol. 1982;16:34.

469 Brüssow H, Eichhorn W, Sotek J, Sidoti J. Prevalence of antibodies to four bovine rotavirus strains in different age groups of cattle. Vet Microbiol. 1990;25:143.

470 Tråvén M, Näslund K, Linde N, et al. Experimental reproduction of winter dysentery in lactating cows using BCV-comparison with BCV infection in milk-fed calves. Vet Microbiol. 2001;81:127.

471 Saif LJ, Redman DR, Moorhead PD, et al. Experimentally induced coronavirus infections in calves: viral replication in the respiratory and intestinal tracts. Am J Vet Res. 1986;47:1426.

472 Storz J, Lin X, Purdy CW, et al. Coronavirus and Pasteurella infections in bovine shipping fever pneumonia and Evans’ criteria for causation. J Clin Microbiol. 2000;38:3291.

473 Crouch CF, Acres SD. Prevalence of rotavirus and coronavirus antigens in the faeces of normal cows. Can J Comp Med. 1984;48:340.

474 Crouch CF, Bielefeldt Ohmann H, et al. Chronic shedding of bovine coronavirus antigen antibody complexes by clinically normal cows. J Gen Virol. 1985;66:1489.

475 Collins JK, Riegel CA, Olson JD, et al. Shedding of enteric coronavirus in adult cattle. Am J Vet Res. 1987;48:361.

476 Parwani AV, Luchelli A, Saif LJ. Identification of group B rotaviruses with short genome electropherotypes from adult cows with diarrhea. J Clin Microbiol. 1996;34:1303.

477 Tsunemitsu H, Saif LJ. Antigenic and biological comparisons of bovine coronaviruses derived from neonatal calf diarrhea and winter dysentery of adult cattle. Arch Virol. 1995;140:1303.

478 Gélinas A, Boutin M, Sasseville M, et al. Bovine coronavirus associated with enteric and respiratory diseases in Canadian dairy cattle display different reactivities to anti-HE monoclonal antibodies and distinct amino acid changes in their HE, S, and ns4.9 protein. Virus Res. 2001;76:43.

479 Kourtesis AB, Gélinas AM, Dea S. Genomic and antigenic variations of the HE glycoprotein of bovine coronaviruses associated with neonatal calf diarrhea and winter dysentery. Arch Virol. 2001;146:1219.

480 Hasoksuz M, Lathrop S, Al-dubaib MA, et al. Antigenic variation among bovine enteric coronaviruses (BECV) and bovine respiratory coronaviruses (BRCV) detected using monoclonal antibodies. Arch Virol. 1999;144:2441.

481 Hasoksuz M, Lathrop SL, Gadfield KL, et al. Isolation of bovine respiratory coronaviruses from feedlot cattle and comparison of their biological and antigenic properties with bovine enteric coronaviruses. Am J Vet Res. 1999;60:1227.

482 Liu L, Hägglund S, Hakhverdyan M, et al. Molecular epidemiology of bovine coronavirus on the basis of comparative analyses of the S gene. J Clin Microbiol. 2006;44:957.

483 Kapikian AZ, Channock RM. Rotaviruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven; 1996:1657.

484 Vonderfecht SL, Eiden JJ, Torres A, et al. Identification of a bovine enteric syncytial virus as a nongroup A rotavirus. Am J Vet Res. 1986;47:1913.

485 Theil KW, McCloskey CM. Molecular epidemiology and subgroup determination of bovine group A rotaviruses associated with diarrhea in dairy and beef calves. J Clin Microbiol. 1989;27:126.

486 Tsunemitsu H, Jiang B, Yamashita Y, et al. Evidence of serologic diversity within group C rotaviruses. J Clin Microbiol. 1992;30:30092.

487 Chinsangaram J, Schore CE, Guterbock W, et al. Prevalence of group A and group B rotaviruses in the feces of neonatal dairy calves from California. Comp Immun Microbiol Infect Dis. 1995;18:93.

488 Hoshino Y, Wyatt RG, Greenberg HB, et al. Serotypic similarity and diversity or rotaviruses of mammalian and avian origin as studied by plaque-reduction neutralization. J Infect Dis. 1984;149:694.

489 Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol Rev. 1989;53:410.

490 Estes MK. Rotaviruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven; 1996:1625.

491 Hoshino Y, Sereno MM, Midthun K, et al. Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity. Proc Natl Acad Sci U S A. 1985;82:8701.

492 Offit PA, Shaw RD, Greenberg HB. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins VP3 and VP7. J Virol. 1986;58:700.

493 Offit PA, Blavat G, Clark HF, et al. Role of gene segments 4 and 9 in determining rotavirus virulence and protection against rotavirus challenge. In: Brown F, Channock RM, Lerner RA, editors. Vaccine 86. New York: Cold Spring Harbor Laboratory; 1986:267.

494 Hussein HA, Parwani AV, Rosen BI, et al. Detection of rotavirus G1, G2, G3, and G11 in feces of diarrheic calves by using polymerase chain reaction—derived cDNA probes. J Clin Microbiol. 1993;31:2491.

495 Parwani AV, Hussein HA, Rosen BI, et al. Characterization of field strains of group A bovine rotaviruses by using polymerase chain reaction—generated G and P type-specific cDNA probes. J Clin Microbiol. 1993;31:2010.

496 Woode GN, Kelso NE, Simpson TF, et al. Antigenic relationships among some bovine rotaviruses: serum neutralization and cross-protection in gnotobiotic calves. J Clin Microbiol. 1983;18:358.

497 Bellinzoni RC, Blackhall JO, Mattion NM, et al. Serological characterization of bovine rotaviruses isolated from dairy and beef herds in Argentina. J Clin Microbiol. 1989;27:2619.

498 Matsuda Y, Nakagomi O, Offit PA. Presence of three P types (VP4 types) and two G types (VP7 types) among bovine rotavirus strains. Arch Virol. 1990;115:199.

499 Snodgrass DR, Fitzgerald T, Campbell I. Rotavirus serotypes 6 and 10 predominate in cattle. J Clin Microbiol. 1990;27:504.

500 Saif LJ. Animal rotaviruses. In: Kapikian AZ, editor. Viral infections of the gastrointestinal tract. New York: Marcel Dekker; 1994:289.

501 Snodgrass DR, Hoshino Y, Fitzgerald TA, et al. Identification of four VP4 serological types (P serotypes) of bovine rotavirus using viral reassortants. J Gen Virol. 1992;73:2319.

502 Snodgrass DR, Fahey KJ, Wells PW, et al. Passive immunity in calf rotavirus infections: maternal vaccination increases and prolongs immunoglobulin G1 antibody secretion in milk. Infect Immun. 1980;28:344.

503 Snodgrass DR, Stewart J, Taylor J, et al. Diarrhea in dairy calves reduced by feeding colostrum from cows vaccinated with rotavirus. Res Vet Sci. 1982;32:70.

504 Saif LJ, Redman DR, Smith KL, et al. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized or nonimmunized cows. Infect Immun. 1983;41:1118.

505 Castrucci G, Frigeri F, Ferrari M, et al. The efficacy of colostrum from cows vaccinated with rotavirus in protecting calves from experimentally induced rotavirus infection. Comp Immun Microbiol Infect Dis. 1984;7:11.

506 Saif LJ, Smith L, Landmeier BJ, et al. Immune response of pregnant cows to bovine rotavirus immunization. Am J Vet Res. 1984;45:49.

507 Archambault D, Morin G, Elazhary Y, et al. Immune response of pregnant heifers and cows to bovine rotavirus inoculation and passive protection to rotavirus infection in newborn calves fed colostral antibodies or colostral lymphocytes. Am J Vet Res. 1988;49:1084.

508 Sharpee RL, Nelson LD, Beckenhauer WH. Immunogenicity of a vaccine containing inactivated bovine rotavirus and coronavirus combined with an Escherichia coli bacterin. Proceedings of the Symposium on Bovine Neonatal Diarrhea, Western Veterinary Conference, Las Vegas. 1988:27.

509 Castrucci G, Frigeri F, Ferrari M, et al. Immunization against bovine rotaviral infection. Eur J Epidemiol. 1989;5:279.

510 Tsunemitsu H, Shimizu M, Hirai T, et al. Protection against bovine rotaviruses by continuous feeding of immune colostrum. Jpn J Vet Sci. 1989;51:300.

511 Mebus CA, White RG, Bass EP, et al. Immunity to neonatal calf diarrhea virus. J Am Vet Med Assoc. 1973;163:880.

512 Snodgrass DR, Wells PW. The influence of colostrum on neonatal rotaviral infections. Ann Rech Vet. 1978;9:335.

513 Snodgrass DR, Wells PW. Passive immunity in rotaviral infections. J Am Vet Med Assoc. 1978;173:565.

514 Woode GN, Jones J, Bridger JC. Levels of colostral antibodies against neonatal calf diarrhea virus. Vet Rec. 1975;97:148.

515 Torres-Medina A, Schlafer DH, Mebus CA. Rotaviral and coronaviral diarrhea. Vet Clin North Am Food Anim Pract. 1985;1:471.

516 Besser TE, Gay CC, McGuire TC, et al. Passive immunity to bovine rotavirus infection associated with transfer of serum antibody into the intestinal lumen. J Virol. 1988;62:2238.

517 Acres SD, Radostits OM. The efficacy of a modified live reo-like virus vaccine and an E. coli bacterin for prevention of acute undifferentiated neonatal diarrhea of beef calves. Can Vet J. 1976;17:197.

518 Crouch CF. Vaccination against enteric rota and coronaviruses in cattle and pigs: enhancement of lactogenic immunity. Vaccine. 1995;3:284.

519 Saif LJ, Smith KL. Enteric viral infections of calves and passive immunity. J Dairy Sci. 1985;68:206.

520 Bürki F, Mostl K, Spiegl E, et al. Reduction of rotavirus, coronavirus and E. coli—associated calf diarrheas in a large-size dairy herd by means of dam vaccination with a triple-vaccine. Zentralbl Veterinarmed B. 1986;33:241.

521 Mebus CE. Bovine rotavirus and calf coronavirus diarrhea. In: Howard JL, editor. Current veterinary therapy (food animal practice) 2. Philadelphia: Saunders; 1986:492.

522 Heckert RA, Saif LJ, Mengel JP, et al. Mucosal and systemic antibody responses to bovine coronavirus structural proteins in experimentally challenge-exposed calves fed low or high amounts of colostral antibodies. Am J Vet Res. 1991;52:700.

523 Snodgrass DR, Ojeh CK, Campbell I, et al. Bovine rotavirus serotypes and their significance for immunization. J Clin Microbiol. 1984;20:342.

524 Hudson D. Rota-coronavirus vaccination of pregnant cows. Mod Vet Pract. 1981;62:226.

525 Eichhorn W, Bachman PA, Baljer G, et al. Vaccination of pregnant cows with a combined rotavirus/E. coli K99 vaccine for preventing diarrhea of newborn calves. Tierarztl Umsch. 1982;37:599-602.

526 Van Openbosch E, Wellemans G, Broes A: Prévention des diarrhées néonatales virales du veau: Traitment de jeunes veaux avec du lait de vaches vaccinées au moyen d’un vaccin anti-Rotavirus inactivé adjuvé. Ann Med Vet. 1982;126:157.

527 Fremont Y: Vaccinations antirotavirus et anticoronavirus chez les bovins: éléments pratiques du choix entre les vaccinations de la vache ou du veau. Rec Med Vet. 1983;159:345.

528 Snodgrass DR. Evaluation of a combined rotavirus and enterotoxigenic Escherichia coli vaccine in cattle. Vet Rec. 1986;119:39.

529 Bellinzoni RC, Blackhall J, Baro N, et al. Efficacy of an inactivated oil-adjuvanted rotavirus vaccine in the control of calf diarrhoea in beef herds in Argentina. Vaccine. 1989;7:263.

530 Cornaglia EM, Fernández FM, Gottschalk M, et al. Reduction in morbidity due to diarrhea in nursing beef calves by use of an inactivated oil-adjuvanted rotavirus—Escherichia coli vaccine in the dam. Vet Microbiol. 1992;30:191.

531 Waltner-Toews D, Martin SW, Meek AH, et al. A field trial to evaluate the efficacy of a combined rotavirus-coronavirus/Escherichia coli vaccine in dairy cattle. Can J Comp Med. 1985;49:1.

532 Offit PA, Clark HF. Maternal antibody—mediated protection against gastroenteritis due to rotavirus in newborn mice is dependent on both serotype and titer of antibody. J Infect Dis. 1985;152:1152.

533 Murakami Y, Nishioka N, Watanabe T, et al. Prolonged excretion and failure of cross-protection between distinct serotypes of bovine rotavirus. Vet Microbiol. 1986;12:7.

534 Brüssow H, Walther I, Fryder V, et al. Cross-neutralizing antibodies induced by single serotype vaccination of cows with rotavirus. J Gen Virol. 1988;69:1647.

535 Snodgrass DR, Fitzgerald TA, Campbell I, et al. Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals. J Clin Microbiol. 1991;29:2668.

536 Woode GN, Zheng S, Rosen BI, et al. Protection between different serotypes of bovine rotavirus in gnotobiotic calves: specificity of serum antibody and coproantibody responses. J Clin Microbiol. 1987;25:1052.

537 Xu Z, Woode GN. Studies on the role of VP4 of G serotype 10 rotavirus (B223) in the induction of the heterologous immune response in calves. Virol. 1993;196:294.

538 Grotelueschen DM, Duhamel GE, Lu W, et al. Possible vaccination failure in beef cow herds caused by infection with rotavirus distinct from the vaccine virus: clinical observations. Proceedings of the 17th World Buiatrics Congress and the 25th Annual Convention of the American Association of Bovine Practitioners, St Paul. 1992:190. August 31–September 4

539 Lu W, Duhamel GE, Benfield DA, et al. Serological and genotypic characterization of group A rotavirus reassortants from diarrheic calves born to dams vaccinated against rotavirus. Vet Microbiol. 1994;42:159.

540 Mebus CA, White RG, Stair EL, et al. Results of a field trial using a reo-like virus vaccine. Vet Med Small Anim Clin. 1972;67:173.

541 Twiehaus MJ, Mebus CA. Licensing and use of the calf scour vaccine. Proceedings of the 77th Annual Meeting of the U.S. Animal Health Association. 1973:55.

542 Twiehaus MJ, Mebus CA, Bass EP. Survey of the field efficacy of reoviral calf diarrhea vaccine. Vet Med Small Anim Clin. 1975;70:23.

543 Mebus CA, Torres-Medina A, Twiehaus MJ, et al. Immune response to orally administered calf reovirus-like agent and coronavirus vaccine. Dev Biol Stand. 1976;33:396.

544 Van Oppenbosch E, Wellemans G, Strobbe R, et al. Évolution des anticorps anti rotavirus dans le lait de vaches traitées en fin de gestation soit par le vaccin anti rota complet, soit par l’adjuvant seul. Comp Immun Microbiol Infect Dis. 1981;4:293.

545 de Leeuw PW, Ellens DJ, Talmon FP, et al. Rotavirus infections in calves: efficacy of oral vaccination in endemically infected herds. Res Vet Sci. 1980;29:142.

546 Bürki F, Schusser G, Szekely H. Clinical, virological and serological evaluation of the efficacy of peroral live rotavirus vaccination in calves kept under normal husbandry conditions. Zentralbl Veterinarmed B. 1983;30:237.

547 de Leeuw PW, Tiessink JWA. Laboratory experiments on oral vaccination of calves against rotavirus or coronavirus induced diarrhea. Zentralbl Veterinarmed B. 1985;32:55.

548 Van Zaane D, Ijzerman J, DeLeeuw PW. Intestinal antibody response after vaccination and infection with rotavirus of calves fed colostrum with or without rotavirus antibody. Vet Immunol Immunopathol. 1986;11:45.

549 Blackmer PE. A practitioner’s experience with experimental reo-coronavirus calf diarrhea vaccine. Proceedings of the 8th Annual Convention of the American Association of Bovine Practitioners, Atlanta. 1975:22. Dec 10–13

550 Thurber ET, Bass EP, Beckenhauer WH. Field trial evaluation of a reo-coronavirus calf diarrhea vaccine. Can J Comp Med. 1977;41:131.

551 McDonough SP, Stull CL, Osburn BI. Enteric pathogens in intensively reared veal calves. Am J Vet Res. 1994;55:1516.

552 Acres SD. Enterotoxigenic Escherichia coli infections in newborn calves: a review. J Dairy Sci. 1985;68:229.

553 Haggard DL. Bovine enteric colibacillosis. Vet Clin North Am Food Anim Pract. 1985;1:495.

554 Jayappa HG, Strayer JG, Goodnow RA. Controlling colibacillosis in neonatal calves. I. Evaluation of multiple-pilus, multiple-capsule, phase-cloned Escherichia coli bacterin. II. Virulence and prevalence of Escherichia coli bearing type 1 pili among isolates from neonatal calf diarrhea. Vet Med/SAC. 1984;78:388.

555 Moon HW, Bunn TO. Vaccines for preventing enterotoxigenic Escherichia coli infections in farm animals. Vaccine. 1993;11:213.

556 Morris JA, Chanter N, Sherwood D. Occurrence and properties of FY(Att25) Escherichia coli associated with diarrhea in calves. Vet Rec. 1987;121:189.

557 Janke BH, Francis DH, Collins JE, et al. Attaching and effacing Escherichia coli infection as a cause of diarrhea in young calves. J Am Vet Med Assoc. 1990;196:897.

558 Zeman DH, Thomson JU, Francis DH. Diagnosis, treatment, and management of enteric colibacillosis. Vet Med. 1989;84:794.

559 Morris JA, Wray AC, Sojka WJ. Passive protection of lambs against enteropathogenic E. coli: role of antibodies in serum and colostrum of dams vaccinated with K99 antigen. J Med Microbiol. 1980;13:265.

560 Sith HW, Halls S. Observations on the ligated intestinal segment and oral inoculation methods on Escherichia infections in pigs, calves, lambs and rabbits. J Pathol Bacteriol. 1967;93:499.

561 Collins NF, Halbur T, Schwenck WH, et al. Duration of immunity and efficacy of an oil emulsion Escherichia coli bacterin in cattle. Am J Vet Res. 1988;49:674.

562 Da Roden L, Smith BP, Spier SJ, Dilling GW. Effect of calf age and Salmonella bacterin type on ability to produce immunoglobulins directed against Salmonella whole cells or lipopolysaccharide. Am J Vet Res. 1992;53:1895.

563 House JK, Smith BP, Dilling GW, Roden LD. Enzyme-linked immunosorbent assay for serologic detection of Salmonella Dublin carriers on a large dairy. Am J Vet Res. 1993;54:1391.

564 Henning MW. Calf paratyphoid. III. The transmission of antibodies to newly born calves. Onderstepoort J Vet Res. 1953;26:45.

565 Robertsson JA, Lindberg AA, Hoiseth S, Stocker BA. Salmonella Typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Infect Immun. 1983;41:742.

566 Smith BP, Habasha FG, Reina-Guierra M, Hardy AJ. Immunization of calves against salmonellosis. Am J Vet Res. 1980;41:1947.

567 Bairey MH. Immunization of calves against salmonellosis. J Am Vet Med Assoc. 1978;173:610.

568 Aitken MM, Jones PW, Brown GTH. Protection of cattle against experimentally induced salmonellosis by intradermal injection of heat-killed Salmonella Dublin. Res Vet Sci. 1982;32:368.

569 Rankin JD, Taylor RJ. An attempt passively to immunize calves against Salmonella infection by vaccination of their dams. Vet Rec. 1970;86:254.

570 Jones PW, Collins P, Aitken MM. Passive protection of calves against experimental infection with Salmonella Typhimurium. Vet Rec. 1988;123:536.

571 Daigneault J, Thurmond M, Anderson M, et al. Effect of vaccination with the R mutant Escherichia coli (J5) antigen on morbidity and mortality of dairy calves. Am J Vet Res. 1991;52:1492.

572 Tyler JW, et al. Immunity targeting common core antigens of gram negative bacteria. J Vet Intern Med. 1990;4:17.

573 González RN, Cullor JS, Jasper DE, et al. Prevention of clinical coliform mastitis in dairy cows by a mutual Escherichia coli vaccine. Can J Vet Res. 1989;53:301.

574 Borelli CL, Weaver LD, Cullor JS. Effect of E. coli J5 vaccination on incidence of clinical coliform mastitis and milk production loss in dairy cows. Proceedings of the Eleventh Annual Western Food Animal Disease Conference, Reno/Sparks, Nevada. 1990. March 7–8

575 Hogan JS, Smith KL, Todhunter DA, Schoenberger PS. Field trial to determine efficacy of an Escherichia coli J5 mastitis vaccine. J Dairy Sci. 1992;75:78.

576 Cullor JS, Fenwick BW, Smith BP. Decreased mortality and severity of infection from salmonellosis in calves immunized with E. coli (strain J5). Proceedings of the Sixty-Sixth Annual Conference of Research Workers in Animal Diseases, Chicago. 1985.

577 Douglas VL, Cullor JS, Tyler JW, et al. Rapid decay of serum IgG recognizing gram negative cell wall core antigens in neonatal calves. Am J Vet Res. 1989;50:1138.

578 Tyler JW, Cullor JS, Thurmond MC, et al. Humoral response in neonatal calves following immunization with Escherichia coli (strain J5): the effects of adjuvant, age, and colostral passive interference. Vet Immunol Immunopathol. 1989;23:333.

579 Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev. 1990;3:66.

580 Songer JG. Clostridial diseases of small ruminants. Vet Res. 1998;29:219.

581 Meer RR, Songer JG. Multiplex PCR method for genotyping Clostridium perfringens. Am J Vet Res. 1997;58:702.

582 Green DS, Green MJ, Hillyer MH, Morgan KL. Injection site reactions and antibody responses in sheep and goats after the use of multivalent clostridial vaccines. Vet Rec. 1987;120:435.

583 Gyles CL. Histotoxic clostridia. In: Gyles CL, Thoen CO, editors. Pathogenesis of bacterial infections in animals. ed 2. Ames, Iowa: Iowa State University Press; 1993:106.

584 Kerry JB. A note on the occurrence of Clostridium chauvoei in the spleen and livers of normal cattle. Vet Rec. 1964;76:396.

585 Nervig RM, Maloy SE, Claus KD, et al. Clostridium septicum infection in cattle in the United States. J Am Vet Med Assoc. 1981;179:479.

586 Schamber GJ, Berg IE, Molesworth JR. Braxy or bradsot-like abomasitis caused by Clostridium septicum in a calf. Can Vet J. 1986;27:194.

587 Batty I, Walker PD. Fluorescent-labelled clostridial antisera as specific reagents. Bull Off Int Epizoot. 1963;59:1499.

588 Thompson A, Batty I. The antigenic efficiency of pulpy kidney disease vaccines. Vet Rec. 1953;65:659.

589 Ballard J, Bryant A, Stevens D, et al. Purification and characterization of the lethal toxin (alpha-toxin) of Clostridium septicum. Infect Immun. 1992;60:784.

590 Williamson ED, Titball RW. A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene. Vaccine. 1993;11:1253.

591 Olander HJ, Hughes JP, Biberstein EL. Bacillary hemoglobinuria: induction by liver biopsy in naturally and experimentally infected animals. Pathol Vet. 1966;3:421.

592 Niilo L, Dorward WJ, Avery RJ. The role of Clostridium novyi in bovine disease in Alberta. Can Vet J. 1969;10:159.

593 Nakamura S, Kimura I, Yamakawa K, et al. Taxonomic relationships among Clostridium novyi types A and B Clostridium haemolyticum and Clostridium botulinum type C. J Gen Microbiol. 1983;139:1473.

594 Erwin BG. Experimental induction of bacillary hemoglobinuria in cattle. Am J Vet Res. 1977;38:1625.

595 Smith LD, Sugiyama H. Botulism: the organism, its toxins, the disease. Springfield, Ill: Charles C Thomas, 1988.

596 Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155.

597 Kozaki S, Kamata Y, Nagai Y, et al. The use of monoclonal antibodies to analyze the structure of Clostridium botulinum type B derivative toxin. Infect Immun. 1986;52:786.

598 Rocke TE. Clostridium botulinum. In: Gyles CL, Thoen CO, editors. Pathogenesis of bacterial infections in animals. ed 2. Ames, Iowa: Iowa State University Press; 1993:86.

599 Greeley RG, Franklin TE. Loin disease. Southwest Vet. 1967;21:31.

600 Wallis AS. Some observations of the epidemiology of tetanus in cattle. Vet Rec. 1963;75:188.

601 Van Rensberg SJ. Tetanus in calves as a sequel to elastration. J South Afr Vet Assoc. 1959;30:29.

602 Rood JI, Cole ST. Molecular genetics and pathogenesis of Clostridium perfringens. Microbiol Rev. 1991;55:621.

603 Fleming S. Enterotoxemia in neonatal calves. Vet Clin North Am Food Anim Pract. 1985;1:509.

604 Buxton D, Morgan KT. Studies of lesions produced in the brains of colostrum deprived lambs by Clostridium welchii (C. perfringens) type D toxin. J Comp Pathol. 1976;86:435.

605 Hart B, Hooper PT. Enterotoxemia of calves due to Clostridium welchii type E. Aust Vet J. 1967;43:360.

606 McGowan G, Moulton JE, Rood SE. Lamb losses associated with Clostridium perfringens type A. J Am Vet Med Assoc. 1958;133:219.

607 Roeder BL, Chengappa MM, Nagaraja TG, et al. Experimental induction of abomasal tympany, abomasitis, and abomasal ulceration by intraruminal inoculation of Clostridium perfringens type A in neonatal calves. Am J Vet Res. 1988;49:201.

608 Roeder BL, Chengappa MM, Nagaraja TG, et al. Isolation of Clostridium perfringens from neonatal calves with ruminal and abomasal tympany abomasitis and abomasal ulceration. J Am Vet Med Assoc. 1987;190:1550.

609 Arsecularatne SN, Panabokke RG, Wijesundra S. The toxins responsible for the lesions of Clostridium sordellii gas gangrene. J Med Microbiol. 1969;2:37.

610 Richey EJ, Palmer GH. Bovine anaplasmosis. Compend Cont Educ (Pract Vet). 1990;12:1661.

611 Richey EJ. Bovine anaplasmosis. In: Howard JL, Smith RA, editors. Current veterinary therapy 4: food animal practice. Philadelphia: Saunders, 1999.

612 Kocan KM, de la Fuente J, Guglielmone AA, Meléndez RD. Antigens and alternatives for control of Anaplasma marginale infection in cattle. Clin Microbiol Rev. 2003;16:698.

613 Henry ET, Norman BB, Fly DE, et al. Effects and use of a modified live Anaplasma marginale vaccine in beef heifers in California. J Am Vet Med Assoc. 1983;183:66.

614 De Wall DT. Anaplasmosis control and diagnosis in South Africa. Ann N Y Acad Sci. 2000;916:474.

615 Kocan KM, Blouin EF, Barbet AF. Anaplasmosis control: past, present, and future. Ann N Y Acad Sci. 2000;916:501.

616 Palmer GH, Rurangirwa FR, Kocan KM, Brown WC. Molecular basis for vaccine development against the ehrlichial pathogen Anaplasma marginale. Parasitol Today. 1999;15:281.

617 Musoke AJ, Palmer GH, McElwain TF, et al. Prospects for subunit vaccines against tick-borne diseases. Br Vet J. 1996;152:621.

618 Palmer GH. Anaplasma vaccines. In: Wright IG, editor. Veterinary protozoan and hemoparasite vaccines. Boca Raton, Fla: CRC Press, 1989.

619 Palmer GH, McElwain TF. Molecular basis for vaccine development against anaplasmosis and babesiosis. Vet Parasitol. 1995;57:233.

620 Blouin EF, Saliki JT, Kocan KM, Rodgers SJ. Evaluation of Anaplasma marginale from tick cell culture as an immunogen for cattle. Ann N Y Acad Sci. 1998;849:253.

621 Zaugg JL, Lincoln SD. Protection enhancement against bovine anaplasmosis by simultaneous administration of Propionibacterium acnes and a commercial vaccine. Agri-Practice. 1995;16:12.

622 de Andrade GM, Machado RZ, Vidotto MC, Vidotto O. Immunization of bovines using a DNA vaccine (pcDNA3.1/MSP1b) prepared from the jaboticabal strain of Anaplasma marginale. Ann N Y Acad Sci. 2004;1026:257.

623 Brown MH, Brightman AH, Fenwick BW, Rider MA. Infectious bovine keratoconjunctivitis: a review. J Vet Intern Med. 1998;12:259.

624 McConnel CS, House JK. Infectious bovine keratoconjunctivitis vaccine development. Aust Vet J. 2005;83:506.

625 Bayley AJ. Bovine biologic charts. Compendium of veterinary products. ed 7. Port Huron, Mich: North American Compendiums; 2003.

626 Lepper AW, Elleman TC, Hoyne PA, et al. Moraxella bovis pili vaccine produced by recombinant DNA technology for the prevention of infectious bovine keratoconjunctivitis. Vet Microbiol. 1993;36:175.

627 Lepper AW, Atwell JL, Lehrbach PR, et al. The protective efficacy of cloned Moraxella bovis pili in monovalent and multivalent vaccine formulations against experimentally induced infectious bovine keratoconjunctivitis (IBK). Vet Microbiol. 1995;45:129.

628 Smith PC, Blankenship T, Hoover TR, et al. Effectiveness of two commercial infectious bovine keratoconjunctivitis vaccines. Am J Vet Res. 1990;51:1147.

629 Lepper AW, Moore LJ, Atwell JL, Tennent JM. The protective efficacy of pili from different strains of Moraxella bovis within the same serogroup against infectious bovine keratoconjunctivitis. Vet Microbiol. 1992;32:177.

630 Bateman KG, Leslie KE, Scholl TP. A field trial of a piliated Moraxella bovis bacterin for the prevention of infectious bovine keratoconjunctivitis. Can Vet J. 1986;27:23.

631 Ruehl WW, Marrs CF, George L, et al. Infection rates, disease frequency, pilin gene rearrangement, and pilin expression in calves inoculated with Moraxella bovis pilin-specific isogenic variants. Am J Vet Res. 1993;54:248.

632 Greene WH, Grubbs ST, Potgieter LN. Detection of shared magnetic antigenic determinants on whole Moraxella bovis pili by use of antisera to cyanogen bromide-cleaved M. bovis pilus protein. Am J Vet Res. 2001;62:1279.

633 Angelos JA, Hess JF, George LW. Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine. Vaccine. 2004;23:537.

634 George LW, Borrowman AJ, Angelos JA. Effectiveness of a cytolysin-enriched vaccine for protection of cattle against infectious bovine keratoconjunctivitis. Am J Vet Res. 2005;66:136.

635 Cerny HE, Rogers DG, Gray JT, et al. Effects of Moraxella (Branhamella) ovis culture filtrates on bovine erythrocytes, peripheral mononuclear cells, and corneal epithelial cells. J Clin Microbiol. 2006;44:772.

636 Davidson HJ, Stokka GL. A field trial of autogenous Moraxella bovis bacterin administered through either subcutaneous or subconjunctival injection on the development of keratoconjunctivitis in a beef herd. Can Vet J. 2003;44:577.

637 Rebhun WC. Diseases of the teats and udder. In: Diseases of dairy cattle. Philadelphia: Williams & Wilkins; 1995:518.

638 Watson DL, McColl ML, Davies HI. Field trial of a staphylococcal mastitis vaccine in dairy herds: clinical, subclinical, and microbiological assessments. Aust Vet J. 1996;74:447.

639 Bayley AJ. Bovine biologic charts. Compendium of veterinary products. ed 7. Port Huron, Mich: North American Compendiums; 2003.

640 Leitner G, Lubashevsky E, Glickman A, et al. Development of a Staphylococcus aureus vaccine against mastitis in dairy cows I. Challenge trials. Vet Immunol Immunopathol. 2003;93:31.

641 Giraudo JA, Calzolari A, Rampone H, et al. Field trials of a vaccine against bovine mastitis. I, Evaluation in heifers. J Dairy Sci. 1997;80:845.

642 Calzolari A, Giraudo JA, Rampone H, et al. Field trials of a vaccine against bovine mastitis. II, Evaluation in two commercial dairy herds. J Dairy Sci. 1997;80:854.

643 Nordhaug ML, Nesse LL, Norcross NL, Gudding R. A field trial with an experimental vaccine against Staphylococcus aureus mastitis in cattle. I. Clinical parameters. J Dairy Sci. 1994;77:1267.

644 Leitner G, et al. MASTIVAC I: Staphylococcus aureus vaccine—prevention of new udder infection and therapeutic effect on cows chronically infected with S. aureus under field conditions. Isr J Vet Med. 2004;59:68.

645 Widel PW. What about Staphylococcus aureus vaccine? Agri-Practice. 1994;15:26.

646 Smith GW, Lyman RL, Anderson KL. Efficacy of vaccination and antimicrobial treatment to eliminate chronic intramammary Staphylococcus aureus infections in dairy cattle. J Am Vet Med Assoc. 2006;228:422.

647 Tollersrud T, Zernichow L, Andersen SR, et al. Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle. Vaccine. 2001;19:3896.

648 Lee JW, O’Brien CN, Guidry AJ, et al. Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosis. Can J Vet Res. 2005;69:11.

649 Morresey PR. Bovine mastitis. In: Howard JL, Smith RA, editors. Current veterinary therapy 4: food animal practice. Philadelphia: Saunders, 1999.

650 Bolton A, Song XM, Willson P, et al. Use of the surface proteins GapC and Mig of Streptococcus dysgalactiae as potential protective antigens against bovine mastitis. Can J Microbiol. 2004;50:423.

651 Fontaine MC, Perez-Casal J, Song XM, et al. Immunisation of dairy cattle with recombinant Streptococcus uberis GapC or a chimeric CAMP antigen confers protection against heterologous bacterial challenge. Vaccine. 2002;20:2278.

652 Mosier DA, Chengappa MM. Anthrax. In: Howard JL, Smith RA, editors. Current veterinary therapy 4: food animal practice. Philadelphia: Saunders, 1999.

653 Turnbull PCB: Anthrax vaccines: past, present, and future. Vaccine. 1991;95:533.

654 Turner AJ, Galvin JW, Rubira RJ, et al. Experiences with vaccination and epidemiological investigations on an anthrax outbreak in Australia in 1997. J Appl Microbiol. 1999;87:294.

655 Sterne M. Avirulent anthrax vaccine. Onderstepoort J Vet Sci. 1946;21:41.

656 Kaufmann AF, Fox MD, Kolb RC. Anthrax in Louisiana, 1971: an evaluation of the Sterne strain anthrax vaccine. J Am Vet Med Assoc. 1973;163:442.

657 Salmon DD, Ferrier GR. Postvaccination occurrence of anthrax in cattle. Vet Rec. 1992;130:140.

658 Ivins B, Fellows P, Pitt L, et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 1995;13:1779.

659 Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine. 1999;17:340.

660 Mikszta JA, Sullivan VJ, Dean C, et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis. 2005;191:278.

661 Galloway DR, Baillie L. DNA vaccines against anthrax. Expert Opin Biol Ther. 2004;4:1661.

662 Baillie L. The development of new vaccines against Bacillus anthracis. J Appl Microbiol. 2001;91:609.

663 Bergsten C. Infectious diseases of the digits. In Greenough PR, Weaver AD, editors: Lameness in cattle, ed 3, Philadelphia: Saunders, 1997.

664 Stokka GL, Lechtenberg K, Edwards T, et al. Lameness in feedlot cattle. Vet Clin North Am Food Anim Pract. 2001;17:189.

665 Baird AN. Interdigital phlegmon (interdigital necrobacillosis). In: Howard JL, Smith RA, editors. Current veterinary therapy 4: food animal practice. Philadelphia: Saunders, 1999.

666 Rebhun WC. Musculoskeletal diseases. In: Diseases of dairy cattle. Philadelphia: Williams & Wilkins; 1995. In Rebhun WC:

667 Checkley SL, Janzen ED, Campbell JR, McKinnon JJ. Efficacy of vaccination against Fusobacterium necrophourm infection for control of liver abscesses and footrot in feedlot cattle in western Canada. Can Vet J. 2005;46:1002.

668 Clark BL, Emery DL, Stewart DJ, et al. Studies into the immunization of cattle against interdigital necrobacillosis. Aust Vet J. 1986;63:107.

669 Saginala S, Nagaraja TG, Lechtenberg KF, et al. Effect of Fusobacterium necrophorum leukotoxoid vaccine on susceptibility to experimentally induced liver abscesses in cattle. J Anim Sci. 1997;75:1160.

670 Clark BL, Stewart DJ, Emery DL, et al. Immunization of cattle against interdigital dermatitis (footrot) with an autogenous Bacteroides nodosus vaccine. Aust Vet J. 1986;63:61.

671 Read DH, Walker RL. Papillomatous digital dermatitis (footwarts) in California dairy cattle: clinical and gross pathologic findings. J Vet Diagn Invest. 1998;10:67.

672 Blowey RW, Sharp MW. Digital dermatitis in dairy cattle. Vet Rec. 1988;122:505.

673 Shearer JK, Hernandez J, Elliott JB. Papillomatous digital dermatitis: treatment and control strategies. II. Compend Cont Educ (Pract Vet). 1998;20:S213.

674 Walker RL, Read DH, Loretz KJ, Nordhausen RW. Spirochetes isolated from dairy cattle with papillomatous digital dermatitis and interdigital dermatitis. Vet Microbiol. 1995;47:343.

675 Rebhun WC, Payne RM, King JM, et al. Interdigital papillomatosis in dairy cattle. J Am Vet Med Assoc. 1980;177:437.

676 Trott DJ, Moeller MR, Zuerner RL, et al. Characterization of Treponema phagedenis—like spirochetes isolated from papillomatous digital dermatitis lesions in dairy cattle. J Clin Microbiol. 2003;41:2522.

677 Berry SL, et al. A prospective randomized field study to determine the efficacy of a Serpens species vaccine combined with topical treatment with lincomycin HCl for treatment of papillomatous digital dermatitis (footwarts) on a California dairy. Bovine Pract. 1998;32:6.

678 Briggs DJ. Rabies in food animals. In: Howard JL, Smith RA, editors. Current veterinary therapy 4: food animal practice. Philadelphia: Saunders, 1999.

679 Acha PN, Szyfres B. Zoonoses and communicable diseases common to man and animals. Washington, DC: Pan-American Health Organization, 1987. Scientific Publication No. 503

680 Rodrigues da Silva AC, Caporale GM, Gonçalves CA, et al. Antibody response in cattle after vaccination with inactivated and attenuated rabies vaccines. Rev Inst Med Trop Sao Paulo. 2000;42:95.

681 Bayley AJ. Bovine biologic charts. Compendium of veterinary products. ed 7. Port Huron, Mich: North American Compendiums; 2003.

682 Sihvonen L, Kulonen K, Neuvonen E. Immunization of cattle against rabies using inactivated cell culture vaccines. Acta Vet Scand. 1994;35:371.

683 Côrtes JA, Rweyemamu MM, Ito FH, et al. Immune response in cattle induced by inactivated rabies vaccine adjuvanted with aluminum hydroxide either alone or in combination with avridine. Rev Sci Tech. 1993;12:941.

684 Aspden K, van Dijk AA, Bingham J, et al. Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle. Vaccine. 2002;20:2693.

685 Rebhun WC. Diseases of the teats and udder. In: Diseases of dairy cattle. Philadelphia: Williams & Wilkins; 1995.

686 Jarrett WF, Campo MS, O’Neil BW, et al. A novel bovine papillomavirus (BPV-6) causing true epithelial papillomas of the mammary gland skin: a member of a proposed new BPV subgroup. Virology. 1984;136:255.

687 Scott DW. Neoplastic skin diseases. In: Howard JL, Smith RA, editors. Current veterinary therapy 4: food animal practice. Philadelphia: Saunders, 1999.

688 Jarrett WF, O’Neil BW, Gaukroger JM, et al. Studies on vaccination against papillomaviruses: immunity after infection and vaccination with bovine papillomaviruses of different types. Vet Rec. 1990;126:473.

689 Jarrett WF, O’Neil BW, Gaukroger JM, et al. Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec. 1990;126:449.

690 Campo MS. Vaccination against papillomavirus in cattle. Clin Dermatol. 1997;15:275.

691 Kirnbauer R, Chandrachud LM, O’Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996;219:37.

692 Thomsett LR. Skin conditions. In: Andrews AH, et al, editors. Bovine medicine: diseases and husbandry of cattle. Oxford: Blackwell Scientific, 1992.

693 Bayley AJ. Bovine biologic charts. Compendium of veterinary products. ed 7. Port Huron, Mich: North American Compendiums; 2003.

694 Meneguzzi G, Kieny MP, Lecocq JP, et al. Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. Vaccine. 1990;8:199.

695 Avki S, Turutoglu H, Simsek A, Unsal A. Clinical and immunological effects of Newcastle disease virus vaccine on bovine papillomatosis. Vet Immunol Immunopathol. 2004;98:9.